[go: up one dir, main page]

WO2008060332A9 - Méthodes pour traiter ou réduire la fatigue musculaire - Google Patents

Méthodes pour traiter ou réduire la fatigue musculaire

Info

Publication number
WO2008060332A9
WO2008060332A9 PCT/US2007/012936 US2007012936W WO2008060332A9 WO 2008060332 A9 WO2008060332 A9 WO 2008060332A9 US 2007012936 W US2007012936 W US 2007012936W WO 2008060332 A9 WO2008060332 A9 WO 2008060332A9
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
exercise
ryrl
subject
compounds
Prior art date
Application number
PCT/US2007/012936
Other languages
English (en)
Other versions
WO2008060332A2 (fr
WO2008060332A8 (fr
WO2008060332A3 (fr
Inventor
Andrew Robert Marks
Original Assignee
Trustess Of Columbia Universit
Andrew Robert Marks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/032405 external-priority patent/WO2007024717A2/fr
Application filed by Trustess Of Columbia Universit, Andrew Robert Marks filed Critical Trustess Of Columbia Universit
Publication of WO2008060332A2 publication Critical patent/WO2008060332A2/fr
Publication of WO2008060332A9 publication Critical patent/WO2008060332A9/fr
Publication of WO2008060332A8 publication Critical patent/WO2008060332A8/fr
Publication of WO2008060332A3 publication Critical patent/WO2008060332A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings

Definitions

  • This invention is in the field of skeletal muscle fatigue, muscle conditions and disorders, and treatments thereof.
  • the sarcoplasmic reticulum functions, among other things, as a specialized intracellular calcium (Ca 2+ ) store.
  • Channels in the SR called ryanodine receptors (RyRs) open and close to regulate the release of Ca 2+ from the SR into the intracellular cytoplasm of the cell. Release of Ca 2+ into the cytoplasm from the SR increases cytoplasmic Ca 2+ concentration.
  • Open probability (Po) of the RyR receptor refers to the likelihood that the RyR channel is open at any given moment, and therefore capable of releasing Ca 2+ into the cytoplasm from the SR.
  • RyRl is found predominantly in skeletal muscle as well as other tissues
  • RyR2 is found predominantly in the heart as well as other tissues
  • RyR3 is found in the brain as well as other tissues.
  • the RyR channels are formed by four RyR polypeptides in association with four FK506 binding proteins (FKBPs), specifically FKBP 12 (calstabinl) and FKBP12.6 (calstabin2).
  • FKBPs FK506 binding proteins
  • Calstabinl binds to RyRl
  • calstabin2 binds to RyR2
  • calstabinl binds to RyR3.
  • the FKBP proteins (calstabinl and calstabin2) bind to the RyR channel (one molecule per RyR subunit), stabilize RyR-channel functioning, and facilitate coupled gating between neighboring RyR channels, thereby preventing abnormal activation of the channel during the channel's closed state.
  • PKA Protein kinase A binds to the cytoplasmic surface of the RyR receptors. PKA phosphorylation of the RyR receptors causes partial dissociation of calstabins from RyRs. Dissociation of calstabin from RyR causes increased open probability of RyR, and therefore increased Ca + release from the SR into the intracellular cytoplasm.
  • Ca 2+ release from the SR in skeletal muscle cells and heart cells is a key physiological mechanism that controls muscle performance, because increased concentration of Ca + in the intracellular cytoplasm causes contraction of the muscle.
  • Excitation-contraction (EC) coupling in skeletal muscles involves electrical depolarization of the plasma membrane in the transverse tubule (T-tubule), which activates voltage-gated L-type Ca 2+ channels (LTCCs).
  • LTCCs trigger Ca 2+ release from the SR through physical interaction with RyRl .
  • the resulting increase in cytoplasmic Ca 2+ concentration induces actin-myosin interaction and muscle contraction.
  • intracellular Ca 2+ is pumped back into the SR via SR Ca2+-ATPase pumps (SERCAs), which is regulated by phospholamban (PLB) depending on the muscle fiber type.
  • SERCAs SR Ca2+-ATPase pumps
  • Fatigue is the process whereby skeletal muscles become weaker with repeated or intense use such as exercise, or as a result of an illness, disorder or disease. Fatigue can result in task failure and it can be a pronounced symptom in a variety of medical conditions including heart failure, renal failure, cancer, and various muscular dystrophies. Over the past decade, it has become evident that the two dominant classical explanations of muscle fatigue, namely, accumulation of lactic acid and intracellular acidosis, do not cause fatigue. In fact, both may be protective mechanisms during high intensity exercise to prevent fatigue (Allen and Westerblad 2004; Pedersen, Nielsen et al. 2004)
  • Muscle contraction depends on the efficient coupling of electrical stimulation of the muscle surface to Ca 2+ release via the ryanodine receptor, the SR Ca 2+ release channel, to th generation of actinmyosin cross bridges. It is evident, then, that a defect in excitation- contraction coupling that resulted in a reduction in the amplitude of the Ca 2+ transient would among other effects, result in impaired contraction and force generation through ineffective myosin cross bridge formation. Eberstein and Sandow suggested inhibition of Ca + release as a likely factor in the fatigue process (Eberstein and Sandow 1963). Reductions in the amplitude of Ca 2+ release evoked during fatiguing stimulation have been reported in multiple muscle preparations(Allen, Lee et al. 1989; Westerblad and Allen 1991; Allen and Westerblad 2001). The time course of recovery from fatigue parallels the time course over which prolonged depression of Ca + release is observed (Westerblad, Bruton et al. 2000).
  • SR Ca 2+ leak was documented in myofibers following intense exercise and in a model of muscular dystrophy (Wang, Weisleder et al. 2005), possibly due to defective skeletal ryanodine receptors (RyRIs).
  • Chronic activation of the sympathetic nervous system (SNS) in the context of heart failure promotes intrinsic skeletal muscle fatigue due to depletion of the phosphodiesterease PDE4D3 from the RyRl complex, RyRl PKA hyperphosphorylation at Serine 2844, calstabinl depletion from the RyRl complex, and a gain-of-function channel defect (Reiken, Lacampagne et al. 2003).
  • JTV519's beneficial effect on muscle fatigue was not solely due to cardiac improvement, as a beneficial effect was still seen when the drug was given to calstabin2 deficient mice which derive no cardiac benefit from treatment with JTV519.
  • JTV519 directly affects muscle function (Wehrens, Lehnart et al. 2005).
  • identical changes in the RyRl macromolecular complex namely depletion of PDE4D3 from the RyRl complex, RyRl PKA hyperphosphorylation at Serine 2844, and calstabinl depletion from the RyRl complex are related in a time-dependent and activity-dependent manner with repeated intense exercise in a mouse model.
  • the contraction of striated muscle is initiated when calcium (Ca 2+ ) is released from tubules within the muscle cell known as the sarcoplasmic reticulum (SR). Calcium release channels, called ryanodine receptors (RyR), on the SR are required for excitation-contraction (EC) coupling.
  • the RyRl receptor is a tetramer comprised of four 565,000 dalton RyRl polypeptides and four 12,000 dalton FK-506 binding proteins (FKBP 12).
  • FKBP 12s are regulatory subunits that stabilize RyR channel function (Brillantes et al., 1994) and facilitate coupled gating between neighboring RyR channels (Marx et al., 1998); the latter are packed into dense arrays in specialized SR regions that release intracellular stores of Ca 2+ , thereby triggering muscle contraction.
  • the RyRl macromolecular complex also includes the catalytic and regulatory subunits of PKA, and the phosphatase PPl (Marx et al., 2001).
  • FKBP 12 One FKBP 12 molecule is bound to each RyRl subunit. Dissociation of FKBP 12 significantly alters the biophysical properties of the channels, resulting in the appearance of subconductance states, and increased open probability (P 0 ) of the channels (Brillantes et al., 1994; Gaburjakova et al., 2001). In addition, dissociation of FKBP 12 from RyRl channels inhibits coupled gating resulting in channels that gate stochastically rather than as an ensemble (Marx et al., 1998). Coupled gating of arrays of RyR channels is thought to be important for efficient EC coupling that regulates muscle contraction (Marx et al., 1998).
  • FKBPs are cis-trans peptidyl-prolyl isomerases that are widely expressed and subserve a variety of cellular functions (Marks, 1996). FKBP 12s are tightly bound to and regulate the function of the skeletal (RyRl) (Brillantes et al., 1994; Jayaraman et al., 1992) and cardiac (RyR2) (Kaftan et al., 1996) muscle Ca 2+ release channels, as well as a related intracellular Ca 2+ release channel known as the type 1 inositol 1,4,5-triphosphate receptor (IP3R1) (Cameron et al., 1997), and the type I transforming growth factor .beta. (TGF. beta.) receptor (T.beta.RI) (Chen et al., 1997).
  • IP3R1 type 1 inositol 1,4,5-triphosphate receptor
  • TGF. beta. transforming growth factor .beta. receptor
  • the invention provides a method for treating, preventing or ameliorating muscle conditions, diseases or disorders, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula-I.
  • the invention provides a method of treating, preventing, or ameliorating of muscle fatigue in a subject, comprising administering to the subject a therapeutically effective amount of a compound having the Formula-I:
  • Ri is selected from the group consisting of H, oxo, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl; wherein each alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl may be substituted or unsubstituted;
  • R 4 is selected from the group consisting of H, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl; wherein each alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl may be substituted or unsubstituted;
  • R 5 is selected from the group consisting Of-NRi 5 Ri 6 , -(CH 2 ) z NRi 5 Ri 6 , -NHNRi 5 Ri 6 , - NHOH, -OR 15 , -C(O)NHNR 15 R 16 , -CO 2 Ri 5 , -C(O)NR 15 R, 6 , -CH 2 X, acyl, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, cycloalkylal
  • R 7 is selected from the group consisting of-ORis, -NRi 5 Ri 6 , -NHNRi 5 Ri 6 , -NHOH, - CH 2 X, alkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • R 8 and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • Rn, Ri 2 , Ri 3 , and Ri 4 independently are selected from the group consisting of H, OH, NH 2 , -NHNH 2 , -NHOH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • 6 , -ORi 5 , -SO 2 R 7 , and -P( O)R 8 R 9 ; and
  • R ⁇ 5 and Ri 6 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally Ri 5 and R] 6 together with the N to which they are bonded may form a heterocycle which may be substituted; the nitrogen in the benzothiazepine ring may optionally be a quaternary nitrogen; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts
  • the compound is not Sl, S2, S3, S4, S5, S6, S7, S9, SI l, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99, or SlOO.
  • the compound is not Sl,
  • the methods treat symptoms. In other embodiments, the methods treat cause and/or symptoms.
  • the compound is described by a chemical formula selected from the group consisting of Formula I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p.
  • the compound is described by a chemical formula selected from the group consisting of Formula I-a, I-b, I-e, I-f, I-g, I-h, 1-1, I-n, I-o, and I-p.
  • the compound is described by a chemical formula selected from the group consisting of Formula I-n, I-o, and I-p.
  • the compound is selected from the group consisting of Sl, S2, S3, S4, S5, S6, S7, S9, Sl 1, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51 , S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99,S100, S
  • the compound is selected from the group consisting of S47, S48, S50, S51, S59, S64, S74, S75, S77, S85, SlOl, S102, S103, S107, S109, Sl 10, S 11 1 , S 117, and S 121.
  • the compound is selected from the group consisting of S68, SlOl, S102, S103, S107, S109, SI lO, SH l, Sl 17, and S121.
  • the compound is S 107. [0020]
  • muscle fatigue is due a skeletal muscle disease or disorder.
  • the skeletal muscle disease or disorder is associated with abnormal function of an RyRl receptor.
  • the methods treat muscle fatigue due to myopathy.
  • the methods treat muscle fatigue due to muscluar dystrophy.
  • the methods treat muscle fatigue due to central core disease.
  • the methods treat malignanat hyperthermia.
  • the muscle fatigue is exercise-induced muscle fatigue, or age-related muscle fatigue.
  • the exercise-induced muscle fatigue is due to prolonged exercise or high-intensity exercise.
  • the subject is suffering from neuropathy, a neurological disease or disorder, a seizure condition, a genetic disease or disorder, a cardiac disease or disorder, an infectious disease, HIV infection, AIDS, a myopathy, a muscular dystrophy, cancer, malnutrition, renal disease, or renal failure.
  • the cardiac disease or disorder is selected from the group consisting of an irregular heartbeat condition, an exercise- induced irregular heartbeat, congestive heart failure, chronic obstructive pulmonary disease, high blood pressure or any combination thereof.
  • the irregular heartbeat condition is selected from the group consisting of atrial or ventricular arrhythmia, atrial or ventricular fibrillation; atrial or ventricular tachyarrhythmia; atrial or ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPTV), and exercise-induced variants thereof.
  • the myopathy is a congenital myopathy.
  • the myopathy is selected from the group consisting of muscular dystrophies, central core diseases, myopathy with cores and rods, mitochondrial myopathies, endocrine myopathies, glycogen storage diseases, myoglobinurias, dermatomyositis, myositis ossificans, familial periodic paralysis, polymyositis, inclusion body myositis, neuromyotonia, and stiff-man syndrome.
  • the myopathy is a muscular dystrophy, central core disease, or malignant hyperthermia.
  • the muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, facioscapulohumeral dystrophy, limb girdle muscular dystrophy, myotonic muscular dystrophy, myotonic dystrophy type I, myotonic muscular type II, Becker's muscular dystrophy, congenital muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy , myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
  • the glycogen storage disease is selected from the group consisting of Pompe's disease, Andersen's disease, and Cori's diseases.
  • the myoglobinuria is selected from the group consisting of McArdle's disease, Tarui disease, and DiMauro disease.
  • the mitochondrial myopathy is selected from the group consisting of Kearns-Sayre syndrome, MELAS syndrome, and MERRF syndrome.
  • the subject is a human.
  • the invention provides a method of treating, preventing, or ameliorating of muscle fatigue in a subject, comprising administering to the subject a therapeutically effective amount of a compound described by a chemical formula selected from the group consisting of Sl, S2, S3, S4, S5, S6, S7, S9, SI l, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85,
  • the compound is not S4, S7, S20, S24, S25, S26, S27, or S36.
  • the muscle fatigue is exercise-induced muscle fatigue.
  • the muscle fatigue is associated with any other disease or condition which is characterized with muscle fatigue.
  • the muscle fatigue is due to a myopathy.
  • the muscle fatigue is due to muscular dystrophy.
  • the muscle fatigue is due to central core disease.
  • the copound is selected from the group consisting of S47, S48, S50, S51, S59, S64, S74, S75, S77, S85, SlOl, S102, S103, S107, S109, Sl 10, Sl 11, Sl 17, and S121, or any enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, and prodrugs thereof.
  • the compound is selected from the group consisting of SlOl, S 102, S 103, S 107, S 109, SI lO, Si l l, Sl 17, and S 121, or any enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, and prodrugs thereof.
  • the compound is S 107.
  • the subject is suffering from an exercise induced muscle fatigue, age-related muscle fatigue, myopathy, neurological disorder or neuropathy, an infectious disease, a chronic disorder, a genetic disease, or any other disease or disorder associated with muscle fatigue.
  • the subject is suffering from a cardiac disease or disorder, HIV Infection, AIDS, muscular dystrophy, cancer, malnutrition, renal disease, renal failure, or any combination thereof.
  • the subject is suffereing from an irregular heartbeat; an exercise-induced irregular heartbeat; congestive heart failure; chronic obstructive pulmonary disease, high blood pressure or any combination thereof.
  • the irregular heartbeat of the subject comprises atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPTV); and exercise-induced variants thereof.
  • the exercise induced muscle fatigue is due to prolonged exercise. In other embodiments, the muscle fatigue is due to high-intensity-exercise.
  • the muscle fatigue is high-intensity-exercise-induced muscle fatigue in a subject. In another embodiment, the muscle fatigue is due to prolonged exercise. In other embodiments, the muscle fatigue is age-related muscle fatigue in a subject. In certain embodiment, muscle fatigue is associated with a disease or disorder. In certain embodiments, muscle fatigue is due to a myopathy. In other embodiments, the muscle fatigue is due to a muscular dystrophy in a subject.
  • the invention provides a method for treating or preventing myopathy in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p or enantiomers, diastereomers, tautomers, pharmaceutically
  • the invention provides methods for treating or preventing muscular dystrophy in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p or enantiomers, diastereomers, tautomers, pharmaceutically
  • the invention provides methods for treating or preventing central core disease in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p or enantiomers, diastereomers, tautomers, pharmaceutically acceptable
  • the invention provides methods for treating or preventing malignant hyperthermia in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • a compound represented by the structure of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p or enantiomers, diastereomers, tautomers,
  • the compound is represented by the structure of Formula I-a, I-b, I-e, I-f, I-g, I-h, 1-1, I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • the compound is selected from the group consisting of Sl, S2, S3, S4, S5, S6, S7, S9, SI l, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99,
  • the compound is not Sl, S2, S3, S4, S5, S6, S7, S9, SI l, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99, or SlOO as described herein.
  • the methods comprise administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • the compound is selected from the group consisting of S68, SlOl, S102, S103, S 104, S107, S108, S109, SI lO, Si l l, S112, S113, S114, S115, S116, Sl 17, Sl 18, Sl 19, S120, S121, S122, and S123, any salt, hydrate, solvate, polymorph, complex, metabolite, pro-drugs thereof, and any combination thereof.
  • the compound is selected from the group consisting of S 101 , S 102, S 103, S 107, S 109, S 1 10, Sl 1 1, Sl 17, and S 121, any salt, hydrate, solvate, polymorph, complex, metabolite, pro-drugs thereof, and any combination thereof.
  • the compound is S 107, any salt, hydrate, solvate, polymorph, complex, metabolite, pro-drug thereof, or any combination thereof.
  • the compound is Sl 17, any salt, hydrate, solvate, polymorph, complex, pro-drug thereof, or any combination thereof.
  • the compounds are administered in as a specific salt, hydrate, solvate, isomer, enantiomer, or in a substantially pure form.
  • the compound Sl 17 is administered, the compound is administered as an isolated compound in a substantially pure form.
  • the symptoms can be muscle fatigue, exercise-induces muscle fatigue, or any other symptoms associated with skeletal muscle defect.
  • the invention provides a method for reducing calpain activity, or plasma creatine kinase activity or level, in a subject so as to treat or reduce skeletal muscle fatigue in the subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I.
  • the invention provides a method for reducing calpain activity, or plasma creatine kinase activity or level, in a subject so as to treat or reduce skeletal muscle damage in the subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I.
  • the invention provides a method for reducing calpain activity, or plasma creatine kinase activity or level, in a subject so as to treat or reduce defective skeletal muscle function in the subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I.
  • the invention provides a method for reducing calpain activity, or plasma creatine kinase activity or level, in a subject so as to treat or dealy the onset of myopathy, for example but not limited to central core disease, or malignant hyperthermia, in the subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I.
  • the invention provides a method for reducing calpain activity, or plasma creatine kinase activity or level, in a subject so as to treat or dealy the onset of muscular dystrophy in the subject, the method comprising administering to the subject a therapeutically effective amount of a compound represented by the structure of Formula I.
  • the compound is represented by the structure of Formula I-n, I- o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes, metabolites or pro-drugs thereof, or any combination thereof.
  • the compound is selected from the group consisting of Sl, S2, S3, S5, S6, S9, Sl 1, S12, S13, S14, S19, S22, S23, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99, SlOO, SlOl, S102, S103, S104, S107, S108, S109, SI
  • the compound is selected from the group consisting of SlOl, S102, S103, S107, S109, SI lO, Si l l, S117, and S121. In one embodiment, the compound is S 107 or a pharmaceutically acceptable salt thereof.
  • the compound is Sl 17 or a pharmaceutically acceptable salt thereof.
  • the compound is not Sl, S2, S3, S4, S5, S6, S7, S9, SI l, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96,
  • the muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, facioscapulohumeral dystrophy, limb girdle muscular dystrophy, myotonic muscular dystrophy, Becker's muscular dystrophy, congenital muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy , myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy .
  • the invention provides methods for treatment, wherein the subject is a human.
  • the subject is a non-human animal selected from the group consisting of: canine, equine, feline, porcine, murine, bovine, foul, sheep, primates, rodents, ovine and bovine.
  • the invention provides methods for treatment, wherein the compound is part of a pharmaceutical composition.
  • the pharmaceutical composition comprises at least one pharmaceutically acceptable excipient.
  • the at least one pharmaceutically acceptable excipient comprises aromatics, buffers, binders, colorants, disintegrants, diluents, emulsifiers, extenders, flavor-improving agents, gellants, glidants, preservatives, skin-penetration enhancers, solubilizers, stabilizers, suspending agents, sweeteners, tonicity agents, vehicles, viscosity-increasing agents or any combination thereof.
  • the pharmaceutical composition further comprises a second active agent.
  • the second active agent is an analgesic.
  • the composition is in a capsule form, a granule form, a powder form, a solution form, a suspension form, or a tablet form, or in the form of an animal feed.
  • the composition is administered via parenteral, enteral, intravenous, intraarterial, intraspinal, intra, intraosseal, intracutaneous, subcutaneous, intradermal, subdermal, transdermal, intrathecal, intramuscular, intraperitoneal, intrasternal, parenchymatous, oral, sublingual, buccal, rectal, vaginal, inhalational, or intranasal administration.
  • the compound is administered using a drug- releasing implant or via osmotic pump.
  • the compound is administered to the subject at a dose sufficient to restore binding of calstabin 1 to RyRl.
  • the compound is administered to the subject at a dose sufficient to enhance binding of calstabin 1 to RyRl . In certain embodiments, the compound is administered to the subject at a dose sufficient to reduce calpain activity. In certain embodiments, the compound is administered to the subject as a dose sufficient to reduce plasma creatine kinase activity or levels. In certain embodiments which treat stress or exercise induced fatigue claims, administering of the compound begins prior to the beginning of (7, 6, 5, 4, 3, 2, 1 days), concurrently with the duration of, at end of , or after end of the exercise or stress condition (1, 2, 3, 4, 5 , 6, 7 days). In certain embodiments, the compound is administered to the subject at a dose of from about 0.01 mg/kg/day to about 20 mg/kg/day. In certain embodiments, the compound is administered to the subject at a dose of from about 0.05 mg/kg/day to about 1 mg/kg/day.
  • the invention provides methods for treating or preventing muscle fatigue in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of a compound that decreases the open probability of the RyRl channel.
  • the invention provides a method of treating or preventing muscle fatigue in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of a compound that decreases Ca2+ current through the RyRl channel.
  • the invention provides a method of treating or preventing muscle fatigue in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of a compound that decreases calcium leak through the RyRl channel.
  • the invention provides a method of treating or preventing muscle fatigue in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of a compound that increases the affinity with which calstabin 1 binds to RyRl. In other embodiments, the invention provides a method of treating or preventing muscle fatigue in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of a compound that decreases dissociation of calstabin 1 from RyRl .
  • the invention provides a method of treating or preventing muscle fatigue in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of a compound that increases rebinding of calstabin 1 to RyRl .
  • the invention provides a method of treating or preventing muscle fatigue in a subject in need thereof, comprising, administering to the subject a therapeutically or prophylactically effective amount of a compound that mimics the binding of calstabin 1 to RyRl.
  • the subject is suffering form a myopathy, a neurological disorder, an infectious disease, a chronic disorder , a genetic disease, or any other disorder or disease which is associated with symptoms of muscle fatigue.
  • diseases or disorders are a cardiac disease or disorder, defective skeletal muscle function, HIV Infection, AIDS, muscular dystrophy, cancer, malnutrition, exercise-induced muscle fatigue, age-associated muscle fatigue, renal disease, renal failure, an irregular heartbeat; an exercise-induced irregular heartbeat; congestive heart failure; chronic obstructive pulmonary disease, high blood pressure or any combination thereof.
  • the irregular heartbeat of the subject comprises atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPTV); and exercise-induced variants thereof.
  • CPTV catecholaminergic polymorphic ventricular tachycardia
  • the subject is a human.
  • the subject is a non-human animal such as a canine, equine, feline, porcine, murine, bovine, foul, sheep, or any other animal in need of treatment.
  • the invention relates to compositions and methods for treating muscle fatigue by administering novel compounds that stabilize ryanodine receptors (RyR), which regulate calcium channel functioning in cells.
  • the invention provides methods for treating or preventing or reducing muscle fatigue by administering 1 ,4-benzothiazepine compounds that are RyR stabilizers.
  • the muscle fatigue in a subject may be caused by a wide variety of acute and chronic pathologies, diseases or conditions, including but not limited to cardiac disease, HIV infection and IDS, muscular dystrophy, cancer, malnutrition, exercise-induced muscle fatigue, age-associated muscle fatigue, renal disease and renal failure.
  • the invention provides for methods for treating or preventing ryanodine receptor calcium leak and muscle fatigue in subjects suffereing from a disease or disorder characterized by muscle fatigue, or in subjects suffering from muscle fatigue as a result of sustained, prolonged and/or strenuous exercise, or chronic stress.
  • the invention provides methods for treating muscle fatigue with calcium release channel stabilizing drugs such RyCaI compounds.
  • the invention provides methods for reducing calpain activity or levels.
  • the invention provides methods to reduce plasma creatine kinase activity.
  • the compounds used in the methods of the present invention modulate calcium-ion channels in cells of the subject. In some embodiments, the compounds used in the methods of the present invention decrease the release of calcium into cells of the subject. In other embodiments, the compounds used in the methods of the present invention limit or prevent a decrease in the level of RyR-bound FKBP in the subject. In other embodiments, the compounds used in the methods of the present invention inhibit dissociation of FKBP and RyR in cells of the subject. In other embodiments, the compounds used in the methods of the present invention increase binding between FKBP and RyR in cells of the subject. In other embodiments, the compounds used in the methods of the present invention stabilize the RyR- FKBP complex in cells of a subject.
  • the compounds used in the methods of the present invention limit, prevent, or treat a leak in a RyR receptor in the subject.
  • the compounds used in the methods of the present invention modulate the binding of RyR and FKBP in the subject.
  • the compounds used in the methods of the present invention reduce the open probability of RyR by increasing the affinity of FKBP for PKA-phosphorylated RyR.
  • RyR is RyRl.
  • FKBP is calstabinl .
  • the methods for treatment of the present invention are directed to treatment of muscle fatigue which is due to sustained or strenuous exercise. In other embodiments, the methods for treatment of the present invention are directed to treatment of muscle fatigue which is due to chronic stress.
  • the present invention is directed to methods of treating or preventing muscle conditions, including but not limited to myopathies, such as muscular dystrophies.
  • the present invention is directed to methods of treating myopathy, in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of one of the compounds of the invention, such as a compound of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, I-m, I-n, I-o, or I-p, or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes or pro-drugs thereof.
  • the methods and compositions of the invention may be used to treat any subject in need thereof.
  • the subject is a mammal, such as a mammal selected from the group consisting of primates, rodents, ovine species, bovine species, porcine species, equine species, feline species and canine species.
  • the subject is a human.
  • the methods and compositions of the invention may be used to treat or prevent conditions, diseases and disorders affecting the muscles, such as myopathies.
  • the methods and compositions of the invention may be used to treat or prevent a myopathy selected from the group consisting of congenital myopathies, muscular dystrophies, mitochondrial myopathies, endocrine myopathies, muscular glycogen storage diseases, myoglobinurias, dermatomyositis, myositis ossificans, familial periodic paralysis, polymyositis, inclusion body myositis, neuromyotonia, and stiff-man syndrome.
  • a myopathy selected from the group consisting of congenital myopathies, muscular dystrophies, mitochondrial myopathies, endocrine myopathies, muscular glycogen storage diseases, myoglobinurias, dermatomyositis, myositis ossificans, familial periodic paralysis, polymyositis, inclusion body myositis, neuromyotonia, and stiff-man syndrome.
  • a myopathy selected from the group consisting of congenital myopathies, muscular dystrophies, mitochondrial
  • the methods and compositions of the invention may be used to treat or prevent a muscular dystrophy.
  • the methods and compositions of the invention may be used to treat or prevent a muscular dystrophy selected from the group consisting of Duchenne muscular dystrophy, facioscapulohumeral dystrophy, limb girdle muscular dystrophy, myotonic muscular dystrophy, Becker's muscular dystrophy, congenital muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy , myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
  • compositions of the invention may be administered using any suitable method known in the art.
  • the compositions of the invention may be administered using a route selected from the group consisting of parenteral, enteral, intravenous, intraarterial, intraspinal, intra, intraosseal, intracutaneous, subcutaneous, intradermal, subdermal, transdermal, intrathecal, intramuscular, intraperitoneal, intrasternal, parenchymatous, oral, sublingual, buccal, rectal, vaginal, inhalational, and intranasal, or using drug-releasing implant, s of treating or preventing myopathy, in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of the compound S 107, or an enantiomer, diastereomer, tautomer, pharmaceutically acceptable salt, hydrate, solvate, complex, or prodrug thereof.
  • the present invention is directed to methods of treating or preventing muscular dystrophy, such as Duchenne muscular dystrophy, in a subject in need thereof, comprising administering to the subject a therapeutically or prophylactically effective amount of the compound S 107, or an enantiomer, diastereomer, tautomer, pharmaceutically acceptable salt, hydrate, solvate, complex, or prodrug thereof.
  • muscular dystrophy such as Duchenne muscular dystrophy
  • Fg-IOO, fg-103, fg-105, fg- 106 indicates mice treated with S36.
  • Fg-IOl, fg-102, fg-104, fg-107 indicates mice treated with PBS.
  • Figures 2A-2F show that there is no substantial difference between the different treatment groups after 7 days of exercise.
  • Figures 2C-2F show results of a treadmill running exercise on day 7. As described, mice were run on the treadmill on an exercise protocol of increasing intensity, shown on the left marked velocity (m/min) in grey.
  • Fig. 2C shows individual traces reflecting the number of visits to the shocking area at the rear of the treadmill over each three minute interval.
  • Fig. 2D shows the number of shocks delivered to each mouse in each three minute interval, on an inverted axis, plotted as points with a three point moving average interpolation for each mouse.
  • Figures 3A-3F show that after 14 days of swimming, there is no significant difference in the swimming velocities of the different treatment groups.
  • Fig. 3 A shows individual mouse velocities
  • Fig. 3 B shows mean velocities for each treatment group
  • n 3 PBS, n - 4 S36.
  • Treadmill running on day fourteen demonstrates a trend toward improved performance in S36 treated mice.
  • An increasing intensity exercise protocol was used, shown on the left marked velocity (m/min) in grey.
  • Fig. 3 C shows individual traces reflecting the number of visits to the shocking area at the rear of the treadmill over each three minute interval.
  • Fig. 3 A shows individual mouse velocities
  • Fig. 3 B shows mean velocities for each treatment group
  • n 3 PBS, n - 4 S36.
  • Treadmill running on day fourteen demonstrates a trend toward improved performance in S36 treated mice.
  • An increasing intensity exercise protocol was used, shown on the left marked velocity (m/min) in grey.
  • FIG. 3 D shows the number of shocks delivered to each mouse in each three minute interval, on an inverted axis, plotted as points with a three point moving average interpolation for each mouse.
  • Figures 4 A, B, C and D show analysis of data on day 16 of exercise regimen.
  • Figs. 4A and 4B shows results of treadmill running on day sixteen that replicates the trend toward improved performance in S36 treated mice. An increasing intensity exercise protocol was used, shown on the left marked velocity (m/min) in black.
  • Fig. 4 A shows individual traces, which reflect the number of visits to the shocking area at the rear of the treadmill over each three-minute interval.
  • Fig. 4 B shows the number of shocks delivered to each mouse in each three minute interval, on an inverted axis, plotted as points with a three point moving average interpolation for each mouse.
  • Fig. 4 A, B, C and D show analysis of data on day 16 of exercise regimen.
  • Figs. 4A and 4B shows results of treadmill running on day sixteen that replicates the trend toward improved performance in S36 treated mice. An increasing intensity exercise protocol was used, shown on the left marked velocity (m/min) in black.
  • Fig. 4 A shows individual traces, which reflect the
  • Figure 4 shows that the trend toward improved performance in S36 treated mice continues on page 16.
  • Figure 5 shows percent improvements in fatigue times and distance run of S36 treated mice compared to PBS vehicle treated mice under the same conditions at each day, as measured by the treadmill assay.
  • FIG. 6 shows that in vivo treatment with S36 (ARM036) allows RyRl to rebind calstabinl despite intense chronic exercise.
  • RyRl was immunoprecipitated from soleus muscle homogenates of mice following 21 days of exercise with or without simultaneous subcutaneous mini-osmotic pump treatment with S36 and then western blotted back for RyRl, phospho-epitope specific RyRl-pS2844, and calstabinl bound to the RyRl macromolecular complex.
  • Figures 7C and 7D provide data illustrating that the RyCaI compound S 107 reduces calpain activity in the mdx mouse muscular dystrophy model during exercise, and indicates that RyCaIs are useful for treating muscle related diseases, such as muscular dystrophies.
  • Figs. 7A and 7B are intentionally left out.
  • FIG. 8A Composition of the RyRl complex in extensor digitorum longus (EDL) muscle following an exercise protocol (consisting of twice daily swimming) lasting the indicated number of days by immunoprecipitation of RyRl and immunoblot for RyR, RyRl-pS2844, and PDE4D3 and calstabinl bound to the receptor.
  • Fig. 8B Densitometric quantification of A, where each value is relative to the total RyRl immunoprecipitated.
  • Fig. 8C Composition of the RyRl complex in EDL muscle following low intensity and high intensity exercise for 5 days.
  • Fig. 8D Densitometric quantification of 8C.
  • the product of a single RyRl immunoprecipitation was separated on a 4-20% gradient polyacrylamide gel, transferred, and probed for both total RyRl and one or more of the modifications noted.
  • the blots shown are representative of three independent experiments.
  • FIG. 9A Immunoblot of the RyRl complex immunoprecipitated from 100 ug of muscle homogenate from human thigh biopsies before and after exercise on day 1 and day 3 (Fig. 9C) of a high intensity (three hours at 57% VO 2 max ) cycling protocol. Control cyclists sat in the exercise room but did not exercise. Immunoblots show total RyRl, RyRl -S2844 PKA phosphorylation, bound calstabinl, and bound PDE4D3.
  • Fig. 9B and Fig.
  • FIG. 10A Time to failure during a single level treadmill assay on 2 month- old call -/- mice and w.t. littermates.
  • Fig. 10B Individual treadmill failure times for each mouse separated by gender.
  • Fig. 10C Body weights of the call -/- mice were reduced.
  • Fig. 10D Scatter plot of failure time versus body weight shows no correlation in either group of mice.
  • Fig. 10E Plasma creatine kinase (CPK) levels at baseline and following a single downhill eccentric treadmill run.
  • Fig. 10F RyRl immunoprecipitated from EDL and immunoblotted for RyR, RyRl-pS2844, PDE4D3, and calstabinl. *, p ⁇ 0.01, Wilcoxon rank-sum test.
  • Figures 1 IA-I IF shows that PDE4D -/- mice have an exercise defect.
  • 1 IA Time to failure during a single level treadmill assay on 2 month-old PDE4D -/- mice and w.t. littermates.
  • 1 IB Individual treadmill failure times for each mouse.
  • 1 C Body weights of the PDE4D -/- mice.
  • HD Scatter plot of failure time versus body weight shows no correlation in either group of mice.
  • CPK Plasma creatine kinase
  • FIG. 12A Time to failure during treadmill assays on indicated days of a 28 day treatment trial with S 107.
  • Fig. 12B Individual treadmill failure times for each mouse on Day 21.
  • Fig. 12C Force-frequency curves of EDL muscle isolated immediately following the 21 st day of exercise and isometrically stimulated in an oxygenated muscle bath. Forces (cN) are normalized to muscle cross sectional area.
  • Fig. 12D Body weights throughout the trial showed no treatment effect.
  • Fig. 12E Treadmill failure times from a parallel experiment in muscle-specific call -/- mice.
  • Fig. 12F RyRl immunoprecipitated from EDL and immunoblotted for RyR, RyRl-pS2844, PDE4D3, and calstabinl . *, p ⁇ 0.01, Wilcoxon rank-sum test.
  • FIGS 13A-13C show that chronic S 107 treatment reduces fatiguability of isolated FDB fibers.
  • Fig. 13A Representative trace from a vehicle treated FDB fiber of fluo-4 fluorescence ( ⁇ F/FO) normalized to the peak during repeated 300 ms long, 120 Hz field- stimulated tetani at a train rate of 0.5. Hz. Isolated cells were continuously perfused with a HEPES buffered Tyrodes solution at room temperature.
  • Fig. 13B Representative tetanic trace from an S 107 treated FDB fiber.
  • Fig. 13A Representative trace from a vehicle treated FDB fiber of fluo-4 fluorescence ( ⁇ F/FO) normalized to the peak during repeated 300 ms long, 120 Hz field- stimulated tetani at a train rate of 0.5. Hz. Isolated cells were continuously perfused with a HEPES buffered Tyrodes solution at room temperature.
  • Fig. 13B Representative tetanic trace from an
  • FIGS 14A-14B show that RyRl from exercised muscle is leaky, with increased Po at resting calcium.
  • Fig. 14A Representative traces of RyRl channel activity at 90 nM [Ca2+]cw from sedentary mice (sed, left column), mice chronically exercised and treated with vehicle (Ex + veh, middle column) and with S 107 (Ex + Sl 07, right column). Single channel openings are plotted as upward deflections; the open and closed (c) states of the channel are indicated by horizontal bars at the beginning of the traces.
  • Corresponding channel open probability (Po), mean open time (To) and frequency of openings (Fo) are shown above each group of traces and represent average values from all experiments.
  • Fig. 14A Representative traces of RyRl channel activity at 90 nM [Ca2+]cw from sedentary mice (sed, left column), mice chronically exercised and treated with vehicle (Ex + veh, middle column) and with S 107 (Ex + Sl 07
  • FIG. 15A Plasma creatine kinase (CPK) activity levels in sedentary and chronically exercised mice with, and without, calstabinl rebinding with S 107.
  • Fig. 15B Calpain activity levels in EDL homogenates measured using a fluorogenic calpain substrate assay. *, p ⁇ 0.01 unpaired t-test, S 107 vs vehicle.
  • CPK creatine kinase
  • Figures 16A-16C show the effect of exercise on the composition of the RyRl complex.
  • Figures 17A-17B show the distribution of 50% reuptake times (tau) in muscle fibers in the presence or absence of S 107 treatment.
  • Figures 18A- 18C show the progressive phosphorylation of RyRl and calstabin 1 depletion from the RyRl complex in an mdx mouse model as a factor of time.
  • Figures 19A-19F show the effect of S 107 on exercise tolerance , body weight, CPK and calpain levels in wt (unaffected) and mdx mice.
  • Figure 20 shows histological slides of wt (unaffected) and mdx mice which are untreated or treated with S 107.
  • muscle fatigue refers to skeletal muscle fatigue and/or weakness. Muscle fatigue can be due to strenuous or repeated physical activity or exercise, chronic stress, disease, disorder, syndrome or any other underlying pathophysiological condition that has symptoms of fatigue, or affects myofibers and/or muscle function. Muscle fatigue is defined as the failure of exercise performance - this can be assessed on an exercise stress test and quantified as the time it takes to fail at the given task (e.g. walking/jogging/running on a treadmill). Failure at the task is defined as termination of the exercise due to inability to continue - this is defined as muscle fatigue.
  • Sustained or prolonged exercise is defined as exercise performed over a defined and measurable time period.
  • Strenuous exercise is exercise to evoke muscle fatigue within a defined time period.
  • Chronic stress is defined as conditions that cause muscle fatigue chronically either due to persistent chronic exercise or stress due to chronic diseases/disorders that are often associated with chronic activation of the sympathetic nervous systems (e.g chronic activation of the "fight or flight " response).
  • the subject's defective skeletal muscle function occurs during chronic obstructive pulmonary disease, hypertension, asthma, or hyperthyroidism.
  • the present invention is directed to compositions and methods for the treatment and prevention of myopathies.
  • myopathy refers to neuromuscular disorders caused by dysfunction in the muscle itself.
  • myopathy encompasses all of the myopathies described herein and also all other myopathies known to those of skill in the art.
  • Myopathies may be inherited (such as many of the muscular dystrophies) or acquired.
  • Myopathic diseases and disorders include, but are not limited to, congenital myopathies, muscular dystrophies (characterized by progressive weakness in voluntary muscles), mitochondrial myopathies, endocrine myopathies, muscular glycogen storage diseases, myoglobinurias, dermatomyositis, myositis ossificans, familial periodic paralysis, polymyositis, inclusion body myositis, neuromyotonia, stiff-man syndrome, common muscle cramps, and tetany.
  • Examples of muscular dystrophies include, but are not limited to, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, limb girdle muscular dystrophy, and myotonic muscular dystrophy, Becker's muscular dystrophy, congenital muscular dystrophy, Distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy , Limb-girdle muscular dystrophy , Myotonic muscular dystrophy, and Oculopharyngeal muscular dystrophy.
  • mitochondrial myopathies include, but are not limited to, Kearns-Sayre syndrome, MELAS and MERRF.
  • MELAS which is an abbreviation of "mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke” is a progressive neurodegenerative disorder.
  • MELAS affects multiple organ systems including the central nervous system (CNS), skeletal muscle, the eye, cardiac muscle, and, more rarely, the gastrointestinal and renal systems.
  • MERFF which is an abbreviation of "myoclonus epilepsy with ragged-red fibers” may cause epilepsy, coordination loss, dementia and muscle weakness.
  • glycogen storage diseases of muscle include, but are not limited to, Pompe's disease, Andersen's disease, and Cori's diseases.
  • myoglobinurias include, but are not limited to McArdle's disease, Tarui disease, and DiMauro disease.
  • RCaI compounds refers to compounds of the general Formula I, I-a, I-b, I-c, I-d, I-e, 1-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, I-p, or II as provided by the invention, and herein referred to as "compound(s) of the invention".
  • the compounds of the invention are referred using a numerical naming system, with compound numbers 1 to 123 provided herein. These numbered compounds are referred to using either the prefix “S” or the prefix “ARM.” Thus, the first numbered compound is referred to either as “Sl” or “ARMOOl”, the second numbered compound is referred to as either “S2” or “ARM002”, the third numbered compound is referred to as either “S3” or “ARM003", and so on.
  • S' “ and the “ARM” nomenclature systems are used interchangeably throughout the specification, the drawings, and the claims.
  • alkyl refers to a linear or branched, saturated hydrocarbon having from 1 to 6 carbon atoms.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, and neohexyl.
  • the term "Ci-C 4 alkyl” refers to a straight or branched chain alkane (hydrocarbon) radical containing from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, and isobutyl.
  • alkenyl refers to a linear or branched hydrocarbon having from 2 to 6 carbon atoms and having at least one carbon-carbon double bond. In one embodiment, the alkenyl has one or two double bonds.
  • the alkenyl moiety may exist in the E or Z conformation and the compounds of the present invention include both conformations.
  • alkynyl refers to a linear or branched hydrocarbon having from 2 to 6 carbon atoms and having at least one carbon-carbon triple bond.
  • aryl refers to an aromatic group containing 1 to 3 aromatic rings, either fused or linked.
  • cyclic group as used herein includes a cycloalkyl group and a heterocyclic group.
  • cycloalkyl group refers to a three- to seven-membered saturated or partially unsaturated carbon ring. Any suitable ring position of the cycloalkyl group may be covalently linked to the defined chemical structure.
  • exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • halogen refers to fluorine, chlorine, bromine, and iodine.
  • heterocyclic group or “heterocyclic” or “heterocyclyl” or “heterocyclo” as used herein refers to fully saturated, or partially or fully unsaturated, including aromatic (i.e., “heteroaryl”) cyclic groups (for example, 4 to 7 membered monocyclic, 7 to 1 1 membered bicyclic, or 10 to 16 membered tricyclic ring systems) which have at least one heteroatom in at least one carbon atom-containing ring.
  • aromatic i.e., "heteroaryl”
  • Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3, or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized.
  • the heterocyclic group may be attached to the remainder of the molecule at any heteroatom or carbon atom of the ring or ring system.
  • heterocyclic groups include, but are not limited to, azepanyl, azetidinyl, aziridinyl, dioxolanyl, furanyl, furazanyl, homo piperazinyl, imidazolidinyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl,
  • bicyclic heterocyclic groups include indolyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, quinuclidinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, benzofurazanyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl] or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro
  • phenyl refers to a substituted or unsubstituted phenyl group.
  • alkyl alkenyl
  • alkynyl alkynyl
  • aryl aryl
  • phenyl cyclic group
  • cycloalkyl heterocyclyl
  • heterocyclo heterocyclo
  • heterocycle may further be optionally substituted with one or more substituents.
  • groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, alkylaryl, heteroaryl, heterocycle and aryl can themselves be optionally substituted.
  • Exemplary substituents may further optionally include at least one labeling group, such as a fluorescent, a bioluminescent, a chemiluminescent, a colorimetric and a radioactive labeling group.
  • a fluorescent labeling group can be selected from bodipy, dansyl, fluorescein, rhodamine, Texas red, cyanine dyes, pyrene, coumarins, Cascade BlueTM, Pacific Blue, Marina Blue, Oregon Green, 4',6-Diamidino-2-phenylindole (DAPI), indopyra dyes, lucifer yellow, propidium iodide, porphyrins, arginine, and variants and derivatives thereof.
  • DAPI 6-Diamidino-2-phenylindole
  • ARMl 18 of the present invention contains a labeling group BODIPY, which is a family of fluorophores based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene moiety.
  • BODIPY is a family of fluorophores based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene moiety.
  • fluorescent label moieties and fluorescence techniques see, e.g., Handbook of Fluorescent Probes and Research Chemicals, by Richard P. Haughland, Sixth Edition, Molecular Probes, (1996), which is hereby incorporated by reference in its entirety.
  • One of skill in the art can readily select a suitable labeling group, and conjugate such a labeling group to any of the compounds of the invention, without undue experimentation.
  • quaternary nitrogen refers to a tetravalent positively charged nitrogen atom including, for example, the positively charged nitrogen in a tetraalkylammonium group (e.g., tetramethylammonium, N-methylpyridinium), the positively charged nitrogen in protonated ammonium species (e.g., trimethyl-hydroamrnoniurn, N-hydropyridinium), the positively charged nitrogen in amine N-oxides (e.g., N-methyl-morpholine-N-oxide, pyridine-N-oxide), and the positively charged nitrogen in an N-amino-ammonium group (e.g., N-aminopyridinium).
  • a tetraalkylammonium group e.g., tetramethylammonium, N-methylpyridinium
  • protonated ammonium species e.g., trimethyl-hydroamrnoniurn, N-hydropyridinium
  • the nitrogen in the benzothiazepine ring of compounds of the present invention may optionally be a quaternary nitrogen.
  • Non-limiting examples include ARM-113 and ARM-119.
  • prodrug as employed herein denotes a compound that, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield compounds of the present invention.
  • a "pro-drug” refers to an agent which is converted into the parent drug in vivo. Pro-drugs are often useful because, in some situations, they are easier to administer than the parent drug. They are bioavailable, for instance, by oral administration whereas the parent drug is not.
  • the pro-drug also has improved solubility in pharmaceutical compositions over the parent drug.
  • the compound carries protective groups which are split off by hydrolysis in body fluids, e.g., in the bloodstream, thus releasing active compound or is oxidized or reduced in body fluids to release the compound.
  • All stereoisomers of the compounds of the present invention are contemplated within the scope of this invention.
  • Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers (e.g., as a pure or substantially pure optical isomer having a specified activity), or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
  • the chiral centers of the present invention may have the S or R configuration as defined by the IUPAC 1974 Recommendations.
  • racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography.
  • the individual optical isomers can be obtained from the racemates by any suitable method, including without limitation, conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.
  • Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of the compound ("substantially pure” compound), which is then used or formulated as described herein. Such “substantially pure” compounds of the present invention are also contemplated herein as part of the present invention.
  • Metabolite as used herein refers to a byproduct produced in vivo, for example in a subject, from a chemical compound.
  • RCaI compounds refers to compounds of the general Formula I, I-a (Ia), I-b (Ib), I-c (Ic), I-d (Id), I-e (Ie), I-f (If), I-g (Ig), I-h (Ih), I-i (Ii), I-j (Ij), I-k (Ik), 1-1 (U), I-m (Im), I-n (In), I-o (Io), I-p (Ip) or II as provided by the invention, and herein referred to as compound(s) of the invention.
  • Such compounds include, but are not limited to, any one or more of the compounds of formulae including, but not limited to, the compounds of formulae Sl, S2, S3, S4, S5, S6, S7, S9, SI l, S12, S13, S14, S19, S20, S22, S23, S24, S25, S26, S27, S36, S37, S38, S40, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S
  • a subject treated by the methods of the invention can include a mammal.
  • Such a mammal can include a human, primate, canine, equine, feline, porcine, murine, bovine, foul, ungulate or sheep.
  • the terms "animal,” “subject” and “patient” as used herein include all members of the animal kingdom including, but not limited to, mammals, animals (e.g., cats, dogs, horses, etc.) and humans.
  • PKA phosphorylation means a reaction in which a phosphate group is substituted for a hydroxy 1 group by the enzyme protein kinase A (PKA).
  • a “pharmaceutical composition” refers to a mixture of one or more of the compounds described herein, or pharmaceutically acceptable salts, hydrates, polymorphs, or pro-drugs thereof, with other chemical components, such as physiologically acceptable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • a compound of the present invention also can be formulated as a pharmaceutically acceptable salt, e.g., acid addition salt, and complexes thereof.
  • a pharmaceutically acceptable salt e.g., acid addition salt, and complexes thereof.
  • the preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of the agent without preventing its physiological effect. Examples of useful alterations in physical properties include, but are not limited to, lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.
  • pharmaceutically acceptable salt means a salt which is suitable for or compatible with the treatment of a patient or a subject such as a human patient or an animal.
  • pharmaceutically acceptable acid addition salt means any non-toxic organic or inorganic salt of any base compounds represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, or I-p, or Formula II, any of their intermediates.
  • Illustrative inorganic acids which form suitable acid addition salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
  • Illustrative organic acids that form suitable acid addition salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids.
  • Either the mono or di-acid salts can be formed and such salts exist in either a hydrated, solvated or substantially anhydrous form.
  • the acid addition salts of compounds of the invention are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
  • a compound of the present invention also can be formulated as a pharmaceutically acceptable salt, e.g., acid addition salt, and complexes thereof.
  • a pharmaceutically acceptable salt e.g., acid addition salt, and complexes thereof.
  • the preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of the agent without preventing its physiological effect. Examples of useful alterations in physical properties include, but are not limited to, lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.
  • the term "pharmaceutically acceptable salt” means a salt that is suitable for, or compatible with, the treatment of a patient or a subject such as a human patient.
  • the salts can be any non-toxic organic or inorganic salt of any of the compounds represented by Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, I-p or any of the specific compounds described herein, or any of their intermediates.
  • Illustrative salt-forming ions include, but are not limited to, ammonium (NH 4 + ), calcium (Ca 2+ ), iron (Fe 2+ and Fe 3+ ), magnesium (Mg + ), potassium (K + ), pyridinium (CsHsNH + ), quaternary ammonium (NR 4 + ), sodium (Na + ), acetate, carbonate, chloride, bromide, citrate, cyanide, hydroxide, nitrate, nitrite, oxide, phosphate, sulfate, maleate, fumarate, lactate, tartrate, gluconate, besylate, and valproate.
  • Illustrative inorganic acids that form suitable salts include, but are not limited to, hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
  • Illustrative organic acids that form suitable acid addition salts include, but are not limited to, mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids.
  • Either mono or di-acid salts can be formed, and such salts exist in either a hydrated, solvated or substantially anhydrous form.
  • the acid addition salts of compounds of Formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, I-p are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
  • the selection of an appropriate salt can be performed by one skilled in the art. For example, one can select salts in reference to "Handbook of Pharmaceutical Salts : Properties, Selection, and Use" by P.
  • solvate means a compound of Formula I, I-a, I-b, I- c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, I-m, I-n, I-o, and I-p, and Formula II or a pharmaceutically acceptable salt of a compound of Formula I, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
  • a suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a "hydrate.”
  • polymorph refers to a particular crystalline state of a substance, having particular physical properties such as X-ray diffraction, IR spectra, melting point, and the like.
  • an "effective amount,” “sufficient amount” or “therapeutically effective amount” of an agent as used herein is that amount sufficient to effect beneficial or desired results, including clinical results and, as such, an “effective amount” depends upon the context in which it is being applied. The response is preventative and/or therapeutic.
  • the term “effective amount” also includes that amount of the compound of Formula I which is “therapeutically effective” and which avoids or substantially attenuates undesirable side effects.
  • treatment is an approach for obtaining beneficial or desired results, including clinical results.
  • beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state and remission (whether partial or total), whether detectable or undetectable.
  • Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • inhibiting dissociation includes blocking, decreasing, inhibiting, limiting or preventing the physical dissociation or separation of an FKBP subunit from an RyR molecule in cells of the subject, and blocking, decreasing, inhibiting, limiting or preventing the physical dissociation or separation of an RyR molecule from an FKBP subunit in cells of the subject.
  • the term "increasing binding” includes enhancing, increasing, or improving the ability of phosphorylated RyR to associate physically with FKBP (e.g., binding of approximately two fold or, approximately five fold, above the background binding of a negative control) in cells of the subject and enhancing, increasing or improving the ability of FKBP to associate physically with phosphorylated RyR (e.g., binding of approximately two fold, or, approximately five fold, above the background binding of a negative control) in cells of the subject.
  • cardiac muscle cell includes cardiac muscle fibers, such as those found in the myocardium of the heart.
  • the present invention provides compounds that are capable of treating and preventing disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. More particularly, the present invention provides compounds that are capable of treating or preventing a leak in RyR channels.
  • “Disorders and diseases associated with the RyR receptors” means disorders and diseases that can be treated and/or prevented by modulating the RyR receptors that regulate calcium channel functioning in cells.
  • “Disorders and diseases associated with the RyR receptors” include, without limitation, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, central core disease, diabetes, and sudden infant death syndrome.
  • Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
  • Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof.
  • CPVT catecholaminergic polymorphic ventricular tachycardia
  • Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence.
  • Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
  • the compounds of the invention are capable of treating and preventing disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells, by repairing the leak in RyR channels, and enhancing binding of FKBP proteins (e.g., calstabinl) to PKA-phosphorylated RyR.
  • FKBP proteins e.g., calstabinl
  • the compounds are useful to prevent and treat muscle fatigue that is associated with the RyR receptors that regulate calcium channel functioning in cells.
  • the compounds of the invention are effective to treat muscle fatigue that results from pathologies, illnesses, diseases, disorders or conditions that are associated with the RyR receptors that regulate calcium channel functioning in cells.
  • disorders and conditions include, but are not limited to, cardiac disease or disorder, defective skeletal muscle function, HIV Infection, AIDS, muscular dystrophy, cancer, malnutrition, exercise-induced muscle fatigue, age-associated muscle fatigue, renal disease, and renal failure.
  • cardiac disorders and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
  • irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPTV); and exercise-induced variants thereof.
  • the compounds of the invention modulate calcium-ion channels in cells of the subject. In another embodiment, the compounds of the invention decrease the release of calcium into cells of the subject. In another embodiment, the compounds of the invention limit or prevent a decrease in the level of RyR-bound FKBP in the subject. In another embodiment, the compounds of the invention inhibit dissociation of FKBP and RyR in cells of the subject. In another embodiment, the compounds of the invention increase binding between FKBP and RyR in cells of the subject. In another embodiment, the compounds of the invention stabilize the RyR-FKBP complex in cells of a subject. In another embodiment, the compounds of the invention prevent, or treat a leak in a RyR receptor in the subject.
  • the modulate the binding of RyR and FKBP in the subject In another embodiment, the compounds of the invention reduce the open probability of RyR by increasing the affinity of FKBP for PKA-phosphorylated RyR. In another embodiment, the compounds of the invention reduce or inhibit calpain activity so as to treat muscle fatigue. In another embodiment, the compounds of the invention reduce plasma creatine kinase levels so as to treat muscle fatigue.
  • the methods of the present invention can be practiced in vitro or in vivo.
  • the methods of the present invention are practiced in an in vitro system (e.g., in a test tube on isolated cellular components).
  • the methods of the invention are practiced in vivo, e.g., in cultured cells or tissues, or in subjects.
  • the present invention provides use of a compound represented by the structure of formula I, I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, 1-1, 1-m, I-n, I-o, and I-p, and Formula II in the preparation of a medicament for treating or preventing muscle disorder or disease, for example but not limited to muscle fatigue in a subject.
  • muscle fatigue can be caused by increased stress such as in individuals exposed to a continued and prolonged exercise regimen, e.g., soldiers or athletes.
  • the compounds of the invention are useful for treating muscle fatigue in individuals exposed to stress due to, for example, an intense exercise regimen.
  • Skeletal muscular disorder and diseases include, but are not limited to, stress induced skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence.
  • RyCaI compounds which treat defects in Ca2 + release channel can be used in methods for treating, reducing or preventing muscle disorders, muscle fatigue, including but not limited to exercise-induced muscle fatigue or muscle damage, muscle fatigue or damage associated with a disease condition, for example but not limited to a myopathy, muscular dystrophy and the like.
  • lactic acid accumulation may not be detrimental have raised questions about the molecular basis underlying skeletal muscle fatigue.
  • hypotheses a role for defective regulation of calcium has been proposed.
  • the invention provides data showing altered function of the major calcium release channel in skeletal muscle sarcoplasmic reticulum (SR), the type 1 ryanodine receptor (RyRl), is required for excitation-contraction coupling (ECC), during chronic exercise.
  • SR skeletal muscle sarcoplasmic reticulum
  • RyRl type 1 ryanodine receptor
  • ECC excitation-contraction coupling
  • PKA hyperphosphorylation contribute to depletion of the RyRl stabilizing subunit calstabinl (FKBP 12) from the channel macromolecular complex resulting in "leaky" channels (increased open probability under conditions when normal channels are not active).
  • the degree of PKA phosphorylation, and depletion of calstabinl and PDE4D3 are correlated with the intensity and duration of exercise and progressive fatigue. Mice with skeletal muscle-specific calstabinl deficiency and PDE4D deficient mice both exhibited significantly impaired exercise capacity.
  • a small molecule, S 107, that specifically causes rebinding of calstabinl to the RyRl channel improved exercise capacity and force generation of isolated muscle during a 21 day exercise protocol.
  • S 107 treated muscle fibers exhibited reduced fatigue, as determined by measurement of intracellular calcium during repeated tetanic contractions. Furthermore, S 107 treated chronically exercised mice exhibited reduced levels of plasma creatine kinase, and calcium-dependent neutral protease calpain activity in muscle homogenates. This demonstrates the existence of a mechanism of muscle fatigue, during chronic or high-intensity exercise, where SR calcium leak due calstabinl depleted RyRl channels leads to defective calcium signaling and skeletal muscle damage.
  • the invention provides use of RyCaI compounds which target molecular mechanisms of muscle fatigue, muscle conditions and disorders, and provide treatments treatment thereof.
  • Calcium release channel stabilizing drugs prevent muscle fatigue by preventing ryanodine receptor calcium leak during sustained or strenuous exercise. Repeated and strenuous activity of skeletal muscle may cause 1) weakness with intense use (also referred to as fatigue), 2) feeling of sore and weak muscles (referred to as perception), and 3) different degrees of muscle degeneration (referred to as dystrophic remodeling).
  • a dominant theory of muscle fatigue has been that accumulation of intracellular lactic acid resulting in intracellular acidosis directly inhibits force production by the myofibrillar proteins (Hill et al., 1929). Indeed, at lower than physiologic temperatures (20 0 C), acidotic changes of intracellular pH were found to accelerate fatigability of skeletal muscles (Hill at al., 1929).
  • intracellular acidosis was found to preserve muscle excitability and relaxation of the myofilaments during sustained increases of intracellular Ca 2+ during repeated or sustained tetanic contractions, and thus protects from muscle fatigue (Pedersen at al. 2004).
  • Fatigue from chronically sustained exercise may be caused by SR Ca 2+ leak resulting from defective closure of the RyRl channel and partial depletion of the SR Ca 2+ store contributing to diminished force production and increased resting [Ca + ]j interfering with muscle relaxation and when sustained causing muscle degeneration.
  • SR Ca 2+ leak resulting from defective closure of the RyRl channel and partial depletion of the SR Ca 2+ store contributing to diminished force production and increased resting [Ca + ]j interfering with muscle relaxation and when sustained causing muscle degeneration.
  • Recent data shows that an evolutionary conserved stress pathway, the fight-or-flight response, specifically controls RyRl Ca 2+ release in skeletal muscle (Gaburjakova et al., 2001 ; Marx et al., 2001) and that abnormal, chronic activation of this stress pathway causes SR Ca + leak contributing to muscle fatigue (Reiken et al., 2003).
  • RyRl /calcium release channels become PKA hyperphosphorylated and depleted of the stabilizing protein calstabinl during exercise.
  • RyCaI compounds of the invention increase the binding affinity of calstabinl to PKA hyperphosphorylated RyRl. These compounds are called “calcium channel stabilizers" or “RyCaIs” and are in a class of 1 ,4-benzothiazepines and related structures.
  • treatment with a RyCaI compound improves exercise performance of mice running on a treadmill.
  • a calcium leak via PKA hyperphosphorylated RyRl channels causes muscle damage due to activation of calcium-dependent proteases and RyCaIs prevent the calcium leak and inhibit muscle damage during chronic exercise.
  • RyCaI compound can be used to treat, prevent or improve muscle fatigue in chronic diseases including but not limited to heart failure, AIDS, cancer, renal failure, chronic obstructive pulmonary disease, hypertension, asthma, hyperthyroidism, chronic muscle fatigue.
  • RyCaI compound can be used to treat or improve muscular dystrophies.
  • treatment with RyCaI compound can prevent or reduce muscle fatigue which can improve exercise performance in individuals who are exposed to sustained chronic stress and/or physical exercise.
  • treatment with RyCaIs can prevent or reduce muscle fatigue which can improve exercise performance in individuals who are exposed to strenuous physical exercise.
  • a key physiologic mechanism that controls skeletal muscle performance is intracellular calcium (Ca 2+ ) release from specialized Ca 2+ stores (the sarcoplasmic reticulum, SR) via ryanodine receptor (RyRl) Ca + release channels.
  • Ca 2+ intracellular calcium
  • SR the sarcoplasmic reticulum
  • RyRl ryanodine receptor
  • destabilization of the RyRl closed state involves depletion of the stabilizing calstabinl (FKBP 12) channel subunit (Reiken et al. 2003; Brillantes et al. 1994).
  • FKBP 12 stabilizing calstabinl
  • Skeletal muscle contraction is activated by SR Ca 2+ release via the type 1 skeletal ryanodine receptor (RyRl).
  • Depolarization of the T-tubule membrane activates the dihydropyridine receptor voltage sensor (Cavl.l) which in turn activates RyRl channels via a direct protein-protein interaction causing the release of SR Ca 2+ stores.
  • Ca 2+ binds to troponin C allowing actin-myosin cross-bridging to occur and sarcomere shortening.
  • Ca 2+ release channels comprise macromolecular complexes consisting of a homotetramer of 560 kDa RyRl subunits that form scaffolds for proteins that regulate channel function including: protein kinase A and the phosphodiesterase PDE4D3, both of which are targeted to the channel via the anchoring protein mAKAP, PPl (targeted via spinophilin), and calstabin 1 (FKBP12).
  • protein kinase A and the phosphodiesterase PDE4D3 both of which are targeted to the channel via the anchoring protein mAKAP, PPl (targeted via spinophilin), and calstabin 1 (FKBP12).
  • RyRl-S2843 (position S2844 in the mouse RyRl sequence) (Reiken, Lacampagne et al. 2003). Phosphorylation at RyRl-S2843 increases the mean open probability of RyRl in the lipid bilayer (Reiken, Lacampagne et al. 2003). RyRl-S2843A mutant channels could not be PKA phosphorylated and did not show the same PKA-dependent increase in open probability. An RyRl -S2843D mutation mimicked PKA phosphorylation with an increased open probability and destabilized open and closed states (Reiken, Lacampagne et al. 2003).
  • SR Ca 2+ leak has been documented as aberrant calcium sparks in myofibers following intense exercise and in a model of muscular dystrophy (Wang, Weisleder et al. 2005), possibly due to defective RyRl function.
  • Chronic activation of the sympathetic nervous system (SNS) during heart failure is associated with early skeletal muscle fatigue and PKA hyperphosphorylation of RyRl at Ser2844 (meaning that on average 3-4 of the four PKA sites in each homotetrameric channel are PKA phosphorylated in heart failure skeletal muscle), calstabinl depletion from the RyRl complex, and a gain-of- function channel defect (Reiken, Lacampagne et al. 2003).
  • RyRl dysfunction in skeletal muscle leads to altered local subcellular Ca 2+ release events (Ward, Reiken et al. 2003).
  • Modifications in the RyRl complex could alter and are likely to limit peak muscle performance, increase muscle fatigue, and contribute to muscle damage during prolonged or high intensity exercise.
  • the invention provides use of a mouse model of chronic, high-intensity, forced exercise to assess the role of the RyRl channel in skeletal muscle fatigue.
  • the RyRl channel macromolecular complex undergoes remodeling during exercise such that it is progressively PKA hyperphosphorylated, and depleted of PDE4D3 and calstabinl .
  • this remodeling is associated with "leaky” channels (increased open probability) and activation of the calcium-activated protease calpain, and leakage of creatine kinase (CPK) into the plasma, which is consistent with muscle damage.
  • CPK creatine kinase
  • these changes are further associated with decreased force production in isolated muscles and impaired exercise capacity and are exacerbated in mice with PDE4D deficiency or muscle specific calstabinl deficiency.
  • Preventing the RyRl channel leak with a calcium channel stabilizer S107, which enhances binding of calstabinl to RyRl, inhibits calpain activation, CPK leak and improves exercise performance.
  • Myotonic dystrophy type 1 (DMl), the most common muscular dystrophy in adults (1 in 7,400 live births), is a multisystemic disorder caused by a CTG trinucleotide repeat expansion in the 3' untranslated region of the myotonic dystrophy protein kinase (DMPK) gene which causes progressive muscle weakness, inherited muscle hyperexitability (myotonia), cardiac conduction defect, cataract, and insulin resistance.
  • DMPK myotonic dystrophy protein kinase
  • RNA DMPK messenger RNA
  • the mutant DMPK messenger RNA (mRNA) containing an expanded CUG repeat is retained in the nucleus and protein levels are reduced.
  • mRNA DMPK messenger RNA
  • the RNA repeat expansion changes the chromatin structure, silences the expression of the flanking SIX5 gene which codes for a transcription factors, and disrupts regulation of gene expression during development and exercise.
  • HSA lR have a myotonic phenotype in the absence of muscle fiber necrosis and the short- versus long-repeat expressing mouse lines show relatively less or more histopathological signs of muscle regeneration and repair, respectively.
  • HSA LR mice with short- or long repeat expression show no signs of muscle weakness and since RyRl alterations have been linked to DMl, the HSA LR mice provide a model to study the effects of exercise and activation of the sympathetic nervous sytem in these mice. After characterizing RyRl channel composition, phosphorylation status, and function, the HSA LR mice can be challenge with sustained exercise tests and treated with RyCaI compounds.
  • transcripts with expanded CUG repeats cause myotonia and muscle degeneration in DMl Since the mechanism by which transcripts with expanded CUG repeats cause myotonia and muscle degeneration in DMl is not known, this would provide 1) study of a genetic animal model of severe fatigue, 2) elucidation of the key molecular mechanism of DMl, and 3) developing a therapeutic rationale for the most common muscular dystrophy in adults.
  • Sustained activation of intracellular stress pathways such as occurring during strenuous physical exercise, for example but not limited to combat, can result in reduced muscle performance and tissue damage.
  • a major determinant of muscle damage may occur due to toxicity of continuously high catecholamine levels resulting in intracellular Ca 2+ leak.
  • Skeletal ryanodine receptor (RyRl) Ca + release channels constitute intracellular scaffolds that integrate PKA-mediated stress signaling and regulation of intracellular Ca 2+ release and therefore determine the gain of EC coupling and muscle function.
  • Chronically increased PKA phosphorylation of RyRl occurring from a chronic hyperadrenergic state in vivo depletes the stabilizing calstabinl subunits resulting in SR Ca 2+ leak and muscle fatigue.
  • these observations extend to an in vivo animal model of fatigue. Therefore, sustained activation of the sympathetic nervous system during continued muscle performance contributes to increased fatigue development and dystrophic skeletal muscle damage.
  • the invention establishes molecular mechanisms of muscle fatigue occurring from chronically sustained muscle performance.
  • the invention provides methods for treating or preventing detrimental intracellular Ca 2+ leak and muscle damage by administering novel 1 ,4-benzothiazepine derivatives.
  • the skeletal ryanodine receptor (RyRl) channel is comprised of 4 RyRl subunits and associated proteins that bind to the cytoplasmic domain of the channel forming a macromolecular signaling complex. Certain aspects of the invention examine mechanisms by which allosteric modulators regulate RyRl function.
  • the invention determines the effects of fatiguing exercise on 1) RyRl PKA phosphorylation; 2) RyRl channel function examined using RyRl channels reconstituted into planar lipid bilayers; 3) Calstabinl binding to RyRl ; 4) intracellular Ca 2+ sparks in isolated myofibers; 5) isolated skeletal muscle function; 6) mitochondrial integrity, 7) in vivo exercise performance, 8) skeletal muscle histology, fiber type composition and oxidative capacity, 9) creatine kinase (CK) plasma levels, 10) RyRl PKA phosphorylation and calstabinl depletion in leukocytes. Calstabinl depletion during chronically sustained exercise and PKA hyperphosphorylation causes RyRl hyperactivity, intracellular Ca 2+ leak, depletion of SR Ca 2+ stores, accelerated fatigue and dystrophic muscle remodeling.
  • treatment with any RyCaI compound normalizes RyR dysfunction and intracellular Ca 2+ leak.
  • RyRl which are protein kinase A (PKA) hyperphosphorylated and "leaky” in heart failure models and during strenuous exercise, can rebind calstabinl after RyCaI compound treatment, which normalizes single channel and improves muscle performance in heart failure. It is likely that RyCaIs in vivo and in cells treated with RyCaIs prevent intracellular Ca 2+ leak and normalize RyRl channel function during sustained exercise.
  • PKA protein kinase A
  • RyCaI compounds improves skeletal muscle fatigue and dystrophic remodeling during strenuous exercise as occurs in combat.
  • two animal models of muscle fatigue swipe and running on a treadmill
  • certain aspects of the invention show that treatment with RyCaI compounds prevents depletion of calstabinl from RyRl, which decreases muscle fatigue, improves performance, and inhibits dystrophic muscle remodeling.
  • Certain aspects of the invention identify molecular mechanisms of muscle fatigue in myotonic dystrophy (DMl).
  • DMl myotonic dystrophy
  • RyCaI compounds improves skeletal muscle fatigue times and dystrophic remodeling in mouse models of myotonic dystrophy.
  • calstabinl and PDE4D3 knockout mice can be used to further explore molecular fatigue mechanisms and dysregulation during sustained exercise states that contribute to intracellular Ca 2+ leak.
  • the compounds of the invention reduce calpain activity.
  • the compounds of the invention reduce plasma creatine kinase activity.
  • aspects of the invention characterize mechanisms that destabilize the closed state of intracellular calcium (Ca + ) release channels during chronic activation of the sympathetic nervous system as occurs during sustained exercise and/or in combat.
  • Other aspects of the invention disclose therapeutic and preventive measures wherein a drug molecule that rebinds calstabinl may prevent skeletal muscle fatigue by normalizing the skeletal (RyRl) ryanodine receptor gating.
  • the invention provides, thorough characterization of the effects of strenuous exercise on RyRl Ca + leak, in vivo and ex vivo muscle performance and energetic metabolism, methods for the use of RyCaI compounds to overcome muscle fatigue and to prevent muscle damage and/or fatigue during strenuous, and/or sustained exercise, and muscle damage and/or fatigue associated with defective skeletal muscle function, or any disease condition.
  • Ceratin aspects of the invention characterize mechanisms that destabilize the closed state of intracellular calcium (Ca 2+ ) release channels which is a prerequisite for muscle relaxation to occur and prevents damage of myofibers from uncontrolled intracellular SR Ca 2+ leak.
  • Chronic activation of the sympathetic nervous system during forced and sustained exercise caused RyRl PKA hyperphosphorylation, calstabinl depletion, and a defective channel closed state are consistent with SR Ca 2+ leak. Since stress and physical performance in combat are considered significantly more severe compared to the animal use protocols, it can be extrapolated that muscle fatigue and dystrophic degeneration from RyRl Ca 2+ leak represents a more severe phenotype in warfighters.
  • Ceratin aspects of the invention address potential therapeutic and preventive measures in that a drug molecule rebinding calstabinl may prevent skeletal muscle fatigue by normalizing the skeletal (RyRl) ryanodine receptor channel gating.
  • PKA Protein kinase A
  • Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci USA. JuI 5 2005;102(27):9607-9612; Ward CW, Reiken S, Marks AR, et al. Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats. Faseb J.
  • Certain aspects of the invention are directed to thorough characterization of the effects of strenuous exercise on RyRl Ca 2+ leak, in vivo and ex vivo muscle performance and energetic metabolism, and the use of RyCaI compounds to improve muscle fatigue times, to increase exercise capacity, and to prevent muscle damage during and/or after strenuous, sustained exercise.
  • Skeletal RyRl are PKA hyperphosphorylated and depleted of calstabinl
  • Beta-adrenergic stimulation increases the gain of the EC coupling when enhanced muscle performance is required during exercise or stress (fight-or-flight response). Binding of catecholamines to ⁇ -adrenoceptors activates a G-protein coupled intracellular signaling cascade, which leads to increased intracellular cAMP concentrations and activation of protein kinase A (PKA).
  • PKA protein kinase A
  • RyRl phosphorylation by PKA increases the channel open probability and SR Ca 2+ release (Reiken et al., 2003; Wehrens et al., 2004).
  • RyRl in skeletal muscle does not depend on Ca + influx via LTCC ⁇ ls to activate SR Ca + release as evidenced by continuous EC coupling in skeletal muscle cells when external Ca 2+ is removed or when Ca + channel blockers are present (Armstrong et al., 1972; Dulhunty et al., 1988 ; Gonzalez-Serratos et al., 1982). Later experimental findings support RyRl activation by physical coupling with LTCC ⁇ ls (Rios et al., 1987; Tanabe et al., 1990). RyRl Ca 2+ leak likely increases the cellular energy demands by compensatory SR Ca 2+ ATPase uptake consuming more ATP which may contribute to earlier skeletal muscle fatigue.
  • Aerobic exercise can be defined as a form of physical exercise that increases the heart rate and enhances oxygen intake to improve performance.
  • Examples of aerobic exercise are running, cycling, and swimming.
  • mice were challenged by aerobic exercise (forced swimming) for 90 mins twice daily. The animals were accustomed to swimming in preliminary training sessions: day -3 twice 30 mins, day -2 twice 45 mins, day -1 twice 60 mins, day 0 and following twice 90 mins. Mice were then exercised for 1, 7, or 21 additional, consecutive days for 90 mins twice daily. Between swimming sessions separated by a 4 hour rest period the mice are kept warm and given food and water. An adjustable-current water pool was used to exercise mice by swimming.
  • An acrylic pool (90 cm long x 45 cm wide x 45 cm deep) was filled with water to a depth of 25 cm.
  • a current in the pool was generated with a pump.
  • the current speed during the swimming session was at a constant speed of 1 1/min flow rate.
  • the water temperature was maintained at 34°C with an electric heater.
  • Age- and weight-matched mice are used to exclude differences in buoyancy from body fat.
  • mice were exposed to swimming for 1, 7, or 21 days followed by immediate sacrifice. Longer exposure to sustained exercise shows a significant increase of RyRl PKA hyperphosphorylation beginning at 7 days and saturating at 21 days.
  • the invention provides RyCaI compounds and their use to enhance skeletal muscle performance and to reduce muscle dysfunction during sustained stress as occurs under combat conditions.
  • Defects in the RyRl Ca 2+ release channel due to dysregulation by PKA allow rationalizing of a therapeutic concept: intracellular SR Ca 2+ leak and muscle dysfunction can be prevented by a drug that increases binding of the stabilizing calstabinl subunit to the RyRl channel complex and thereby inhibits SR Ca 2+ leak and dystrophic muscle remodeling from sustained stress or exercise. Applying a drag to prevent SR Ca 2+ leak can therefore enhance a variety of important physiologic skills which are prone to stress-induced dysfunction.
  • the invention provides that enhanced binding of calstabinl to RyRl by RyCaI compounds prevents muscle fatigue.
  • pharmacologic activation ⁇ -adrenergic receptor agonists
  • the invention provides pharmacologic approaches based on allosteric modulation of RyRl that can result in improved human performance during sustained stress and prevent adverse tissue damage and shorten recovery times.
  • RyRl PKA phosphorylation quantification of skeletal RyRl channel phosphorylation by protein kinase A (PKA) following sustained exercise for 2 days, 1 week, and 3 weeks using two independent techniques (RyRl PKA phospho-epitope detection by specific antibody; incorporation of radiolabeled phosphate by backphosphorylation essay).
  • PKA protein kinase A
  • RyRl CaMKII phosphorylation quantification of skeletal RyRl channel phosphorylation by Ca + -calmodulin protein kinase II (CaMKII) following sustained exercise for 2 days, 1 week, and 3 weeks using RyRl CaMKII phospho-epitope detection by specific antibody essay developed in our laboratory. This will allow characterizing specific defects resulting from chronic PKA phosphorylation and/or secondary activation of CaMKII signaling by intracellular Ca 2+ leak mechanisms.
  • CaMKII Ca + -calmodulin protein kinase II
  • Calstabinl depletion in the RyRl complex quantification of depletion of the channel stabilizing subunit calstabinl (FKBP 12) from the RyRl channel complex by immunoprecipitation techniques following sustained exercise for 2 days, 1 week, and 3 weeks. Calstabinl depletion occurs from Ser2843 phosphorylation by PKA.
  • RyRl functional defects in vivo development of "leaky” RyRl channels: electrophysiologic characterization of RyRl single-channel activity and open probability following sustained exercise for 2 days, 1 week, and 3 weeks. This allows for a comprehensive and sensitive assessment of SR Ca 2+ release channel defects and leak mechanisms that are known to contribute to muscle fatigue. Moreover, these data will allow developing a rationale for preventive treatment of RyRl Ca 2+ leak using a small lead RyCaI compounds.
  • Improvement of fatigue from sustained exercise quantification of in vivo fatigue using two independent exercise performance tests: swimming and running on a treadmill.
  • the treadmill test will be combined with electrocardiogram telemetry in a subgroup of animals to allow for objective correlation of increased heart rates during exercise with fatigue symptoms.
  • plasma and muscle catecholamine levels will be determined to verify sustained activation of the sympathetic nervous system.
  • Three weeks of maximal fatiguing swimming exercise induces progressive RyRl dysfunction and dystrophic skeletal muscle changes during a low flow rate of 1 1/min (baseline condition which prevents mice from floating passively).
  • video tracking system can be used (San Diego Instruments Incorporated) which automatically tracks and digitizes spatio-temporal movements of 8 mice. Improvement of fatigue will be assessed by time to fatigue (defined as significant increase in 2D distance or activity over time).
  • Isolated skeletal muscle function ex vivo characterization of intrinsic muscle resistance to fatigue stimulation or single-twitch contraction protocols following sustained exercise with placebo or a RyCaI compound treatment for 2 days, 1 week, and 3 weeks.
  • Two different forms of isolated skeletal muscles will be tested: extensor digitorum longus for a fast-twitch muscle and soleus muscle for a slow-twitch muscle. This test can determine the effect of RyCaI compounds on skeletal muscle under fatiguing exercise, or disease conditions. Skeletal muscle contraction and relaxation is critically dependent on intracellular Ca + metabolism and RyRl function and therefore a highly sensitive test.
  • Intracellular Ca 2+ leak and SR Ca 2+ content in isolated skeletal myofibers assessment of isolated skeletal muscle myofibers loaded with fluo-4 Ca 2+ indicators for resting SR Ca 2+ leak using intracellular Ca 2+ sparks. SR Ca 2+ content will be assessed by caffeine pulse protocols which result in complete release of the free SR Ca + pool. Previous studies have documented calcium leak resulting from a chronic hyperadrenergic state in myofibers of rats with heart failure (Reiken 2003; Ward 2003; Gomez 2001 ; Cheng 1996)
  • Mitochondria are key players in cell death, and the spatial proximity of RyRl Ca 2+ release and mitochondrial Ca 2+ uptake suggest, that SR Ca 2+ leak during strenuous exercise can cause mitochondrial Ca + overload which impacts on mitochondrial structure and function and may trigger cell death.
  • Caspase-12 is localized in the SR, is regulated by Ca 2+ , and participates in the SR stress-induced apoptosis pathway (Yoneda et al., 2001).
  • the invention characterizes the effects of fatiguing exercise on mitochondrial membrane potential by rhodamine 123 uptake, mitochondrial swelling indicating mitochondrial permeability transition by 520 nm spectrophotometry and light scatter, the amount of intra-mitochondrial Ca 2+ by organelle incubation with 45 Ca 2+ followed by radioactivity quantification with a liquid scintillation counter, measurement of cytochrome c from release mitochondria coactivating caspases, and staining of muscle preparations for TUNEL-positive cell nuclei.
  • the in vivo effects of RyCaI compounds treatment on mitochondrial integrity and function will be assessed.
  • Activation of intracellular proteases fragments RyRl A direct link exists between the cytosolic Ca + elevations and the proteolysis of intracellular targets through the activation of Ca 2+ -dependent proteases, including calpains and caspases. Calpain activation is part of the apoptosis machinery. Increased activation of the ubiquitous calpains has been found in the mouse model of Duchenne muscular dystrophy (DMD), but null mutations of muscle specific calpain causes limb girdle muscular dystrophy 2A (LGMD2A) (Tidball et al., 2000).
  • DMD Duchenne muscular dystrophy
  • LGMD2A limb girdle muscular dystrophy 2A
  • Dystrophic changes from sustained exercise may result in muscle fiber necrosis and progressive muscle wasting and weakness. Histological analysis of skeletal muscles will include analysis for eosinophilic hypercontracted muscle fibers, necrotic fibers, ongoing muscle regeneration, and the proliferation of fibroblasts within muscle tissue since the replacement of muscle tissue by connective tissue (fibrosis) is a major cause of permanent muscle weakness. Accordingly, RyCaI compounds can be tested for inhibition of these changes. Conventional histology techniques will allow to assess variability in fiber size, split fibers, and centralized nuclei.
  • Fiber typing by histochemistry in skeletal muscles Historically, the most widely used classification of fiber types is based on the mATPase (myofibrillar adenosine triphosphatase) activity by histochemistry which distinguishes between type I (low activity) and type II (high activity) fibers (Brooke et al., 1970). By characterizing the pH lability of the mATPase, type II fibers were further subdivided into HA and HB fibers.
  • mATPase myofibrillar adenosine triphosphatase
  • type I intermediate slow-twitch oxidative
  • type II A red fast-twitch oxidative- glycolytic
  • type IIB white fast-twitch glycolytic fibers.
  • Quantitative histochemistry can be used to determine mATPase, succinate dehydrogenase, and ⁇ -glycerophosphate dehydrogenase and cross-sectional areas in MHC-based fiber type changes in oxidative and glycolytic capacities resulting from sustained exercise and/or RyCaI compound treatment.
  • Fiber typing by immunocytochemistry in skeletal muscles To quantitate changes in myonuclear number and location and to distinguish from nuclei of interstitial cells, morphometry by fluorescence microscopy using stains for nuclei (DAPI) and basement membrane (anti-laminin) will be applied. This technique will be particularly important to precisely determine cross-sectional area and number of nuclei in muscle fibers.
  • the technique allows for combined immunocytochemistry with the following affinity-purified antibodies: C-terminal RyR2-5029, phospho-epitope-specific RyRl-p2844 (Wehrens et al., 2004), calstabinl (FKBP12) (Jayaraman et al., 1992), isoform-specific myosin heavy chain (MHC) antibodies (Rivero et al. 1999), and ⁇ -actinin (Ruehr et al., 2003) using a previously established protocol with 10 ⁇ m thick cryostat sections of EDL or soleus muscles (Moschella et al., 1995).
  • This approach will allow us to classify myofibers and phenotypic changes according to MHC content, metabolic activity, fiber size, RyRl PKA phosphorylation, and calstabinl binding occuring from sustained exercise and/or RyCaI compound treatment. Further, the fiber type and immunocytochemistry data will be correlated to isolated skeletal muscle function, general histologic data, histochemistry, RyRl single-channel function, and mitochondria data.
  • fiber type-specific improvement of calstabinl binding to RyRl and RyRl PKA phosphorylation can be determined in the presence or absence, or after RyCaI compound treatment in ⁇ -actinin positive compartments (Z-disk), and for increased calpain expression in the myofibrillar area (Z disks; compartment containing RyRl channels) of muscle fibers.
  • Skeletal muscle oxidative capacity Muscle oxidative activity correlates with skeletal muscle adoption to aerobic exercise. As a general test, fast- and slow-twitch skeletal muscle oxidative enzyme activity will be assessed by spectrophotometric assessment of the citric acid cycle and citrate synthase activity in muscle homogenates. Activity as determined as the complex from coenzyme A and oxaloacetate is expected to be increased as reported by a group using a similar protocol (Evangelista et al., 2003). This test will be used to confirm changes in oxidative capacity seen by histochemistry.
  • CK creatine kinase
  • Creatine kinase (CK) and lactate dehydrogenase (LDH) plasma concentrations can be determined as indicators or muscle damage and inflammation after exhaustive exercise and to determine effect due to RyCaI compound treatment.
  • RyRl composition and function in white blood cells RYRl in immune cells functions as a Ca + release channel during B- or T-cell receptor-stimulated activation (Sei t al., 2002; Kraev et al., 2003).
  • peripheral white blood cells are isolated from mouse blood samples by centrifugation.
  • Leukocytes (10 6 /ml) are loaded with 1 ⁇ m acetoxy-methyl ester of fluo-3 (Molecular Probes, Eugene, OR) by incubation for 30 mins at 25 0 C and caffeine sensitivity of intracellular Ca 2+ release is tested. Compostion and PKA phosphorylation of the RyRl channel complex will be characterized.
  • Investigating RyRl in white blood cells will allow monitoring temporal changes during sustained exercise and RyCaI compound treatment in vivo.
  • the RyRl macromolecular signaling complex plays a key role in modulating activation of the channel and excitation-contraction coupling by the sympathetic nervous system.
  • mAKAP targets PKA and the phosphodiesterase PDE4D3 to the channel and the phosphatase PPl is targeted to the channel by the targeting protein spinophilin.
  • This signaling module controls PKA phosphorylation of RyR2 at Ser2843 as part of the "fight-or-flight" stress response.
  • Ser2843 PKA phosphorylation sites in each tetrameric RyRl channel are transiently PKA phosphorylated resulting in increased activity of the RyRl channel.
  • Activation of the RyRl due to PKA phosphorylation occurs because PKA phosphorylation decreases the binding affinity of the stabilizing protein calstabinl (FKBP 12) for the channel resulting in increased sensitivity of the channel to Ca 2+ -dependent activation.
  • PDE4D3 in the RyRl macromolecular signaling complex plays a protective role against PKA hyperphosphorylation and forms a negative feedback loop during PKA activation.
  • the phosphodiesterases in the RyRl complex by rapidly degrading local cAMP and thereby terminating channel activation by PKA. Mice that are deficient in PDE4D3 or calstabinl in the RyRl complex will be tested for accelerated muscle fatigue.
  • both calstabinl and PDE4D3 in the RyR2 complex can be thought of as being "protective" against muscle dysfunction during excessive exercise or stress.
  • additional components of the RyRl macromolecular complex are protective against fatigue as these molecules could potentially be novel therapeutic targets and/or identify adverse pharmaceutical agents for preventing fatigue during intense stress in warfighters.
  • DMl has a DM-like phenotype.
  • the HSA LR myotonic phenotype includes variable degress of histopathological signs of muscle degeneration and repair, which correspond to the expression of more toxic, long or less, toxic short repeat variants.
  • susceptibility to muscle fatigue will be investigated using swimming and treadmill running protocols.
  • implantable telemetry devices will be implanted two weeks before the mice are subjected to an exercise-stress protocol as described. Upon completion of the experiment, mice will be sacrificed and muscles will be flash- frozen in liquid nitrogen or further processed for histological assays.
  • RyRl PKA phosphorylation levels of the components of the RyR2 macromolecular complex including calstabinl, PKA, RII, mAKAP, PPl, spinophilin, PDE4D3, CaMKII, and single channel properties will be examined. The following properties are determined: Ca + sensitivity of activation and inhibition, Mg 2+ inhibition, and changes from in vivo RyCaI treatment.
  • ryanodine will be applied to the channel to confirm RyR identity.
  • the HSA LR mouse will allow to test beneficial effects of RyCaI compounds in an extreme model of genetic muscle fatigue and dystrophy.
  • the invention provides that RyCaI compounds can restore normal function to hyperphosphorylated RyRl . Furthermore, use of PDE4D knockout and FKBP 12 haploinsufficient mice allows determination whether RyCaI compound prevent muscle fatigue.
  • SR Ca + leak is unique since it is a direct cause of muscle fatigue intrinsic to myofibers which is not reversible in the acute setting.
  • a drug like any RyCaI compound which fixes the SR Ca 2+ leak by binding calstabinl to the channel and stabilizing the closed state even during stress therefore helps to prevent accelerated fatigue development and promotes longer performance despite sustained stress (Wehrens, 2005).
  • the pharmacotherapy is unique since it targets a central fatigue mechanism and potentially prevents toxic effects of intracellular Ca + leak.
  • the molecular mechanism of this pharmocotherapy is unique, since it treats a specific defect contributing to muscle fatigue and since the mechanism of RyCaI action is stabilization of normal RyRl channel closure by increasing the calstabinl binding affinity, which is distinct from historical approaches that block ion channel function.
  • SR Ca 2+ leak was documented in myofibers following intense exercise and in a model of muscular dystrophy,(Wang et al., 2005), possibly due to defective skeletal ryanodine receptors (RyRIs).
  • SNS sympathetic nervous system
  • SM skeletal muscle
  • RyRl dysfunction in the skeletal muscle leads to altered local subcellular Ca 2+ release events and impaired global calcium transients (Ward et al., 2003).
  • changes in the RyRl macromolecular complex namely depletion of PDE4D3 from the RyRl complex, RyRl PKA hyperphosphorylation at Serine 2844, and calstabinl depletion from the RyRl complex are related in a time-dependent and activity-dependent manner with repeated intense exercise in a mouse model.
  • These biochemical changes in the RyRl macromolecular complex regulation and function are stable following prolonged exercise and recover slowly over days to weeks.
  • Exercise promotes numerous positive effects on an organism, from improvement in cardiovascular performance to increased glucose uptake and normalization of fuel metabolism (Goodyear and Kahn 1998; Pollock, Franklin et al. 2000).
  • heart failure light exercise training has been shown to improve skeletal muscle strength and reduce fatigue, perhaps through adaptation to more aerobic muscle properties (Minotti, Johnson et al. 1990; Lunde, Sjaastad et al. 2001; Meyer 2006).
  • high intensity exercise such as that performed by a marathon runner or a long distance cyclist results in significant muscle damage and can impair task performance for days or weeks after a single event (O'Reilly, Warhol et al. 1987; Balnave and Thompson 1993; Komulainen and Vihko 1994).
  • Described herein is also a mouse model of intense physiological exercise to examine the changes in RyRl function and ECC experienced by elite athletes, soldiers, or others under intense stressful activity.
  • a physiological exercise regimen was constructed that did not exclusively involve isometric or eccentric contraction of the hind limb. While this resulted in less dramatic evidence of exercise-induced muscle damage than pure eccentric contractions, the data presented are more readily generalized.
  • S 107 corrected the leak in RyRl from chronically exercised mice as measured in a lipid bilayer at low resting Ca 2+ levels.
  • Ca 2+ leak resulting from the overactive skeletal ryanodine receptors was not directly visualized in isolated muscle fibers, as calcium sparks were infrequent under all conditions tested, which is consistent with most reports that sparks in skeletal muscle are rare except under certain highly pathological conditions such as hypoosmotic shock or muscular dystrophy (Isaeva, Shkryl et al. 2005; Rios 2005; Wang, Weisleder et al. 2005).
  • the present invention provides methods and uses which comprise administering compounds of Formula I:
  • R ⁇ is selected from the group consisting of H, oxo, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl; wherein each alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl may be optionally substituted;
  • R 4 is selected from the group consisting of H, alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl; wherein each alkyl, alkenyl, aryl, alkylaryl, cycloalkyl, heteroaryl, and heterocyclyl may be optionally substituted;
  • R 6 is selected from the group consisting of -0R ! 5 , -NHNRi 5 Ri 6 , -NHOH, -NR 15 Ri 6 , -CH 2 X, acyl, alkenyl, alkyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be optionally substituted;
  • R 7 is selected from the group consisting Of-ORi 5 , -NRi 5 Ri 6 , -NHNR 15 Ri 6 , -NHOH, -CH 2 X, alkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be optionally substituted;
  • R 8 and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be optionally substituted;
  • Rio is selected from the group consisting of -NR I 5 R J 6 , OH, -SO 2 Rn, -NHSO 2 Rn, C(O)(R 12 ), NHCO(R, 2 ), -OCO(R 12 ), and -P(O)R 13 R 14 ;
  • R 1 1 , R 12 , R 13 , and R] 4 independently are selected from the group consisting of H, OH, NH 2 , - NHNH 2 , -NHOH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be optionally substituted;
  • 6 , -NRi 5 R] 6 , -ORi 5 , -SO 2 R 7 , and -P( O)R 8 R 9 ; and
  • Ri 5 and R] 6 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be optionally substituted; and optionally Ri 5 and Ri 6 together with the N to which they are bonded may form a heterocycle which may be substituted; the nitrogen in the benzothiazepine ring may optionally be a quaternary nitrogen; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates,
  • R 2 when q is O and n is 1 or 2, then R 2 is not -C(O)Me, -C(O)Et, - S(O) 2 Me, or -S(O) 2 Et; further provided that when q is 1, and R is Me, Cl, or F at the 6 position of the benzothiazepene ring, then R 2 is not H, Me, -C(O)H, -C(O)Me, -C(O)Et, -C(O)Ph, - S(O) 2 Me, or -S(O) 2 Et; and further provided that when q is 1, n is O, and R is OCT 3 , OH, CpC 3 alkoxyl at the 7 position
  • the present invention provides methods and uses which comprise administering compounds of Formula I, as described above, with the proviso that said compound is not S24 or S68. [00210] In one embodiment, the present invention provides methods and uses which comprise administering compounds of Formula I-a:
  • R 6 is selected from the group consisting of -ORi 5 , -NHNR, 5 R
  • R 7 is selected from the group consisting of H, -ORi 5 , -NRi 5 Ri 6 , -NHNRi 5 Ri 6 , -NHOH, - CH 2 X, alkyl, akenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, akenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • Rg and R 9 independently are selected from the group consisting of -OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • m is O, 1, 2, 3, or 4;
  • Rn, R 12 , R 13 , and R 14 independently are selected from the group consisting of H, OH, NH 2 , - NHNH 2 , -NHOH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
  • 5 Ri 6 , -NRi 5 Ri 6 , -ORi 5 , -SO 2 R 7 , and -P( O)R 8 R 9 ; and
  • R 15 and Ri 6 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R) 6 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted; the nitrogen in the benzothiazepine ring may be optionally a quaternary nitrogen; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes
  • the present invention provides methods and uses which comprise administering compounds of formula I-b:
  • R' and R" are independently selected from the group consisting of H, halogen, -OH, -NH 2 , -NO 2 , -CN, -CF 3 , -OCF 3 , -N 3 , -SO 3 H, -S(O) 2 alkyl, -S(O)alkyl, -OS(O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino; and wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)
  • R 2 and n are as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • R' is H or OMe
  • R" is H.
  • the present invention provides methods and uses which comprise administering compounds formula of I-c:
  • each R, R 7 , q, and n is as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula I-c, wherein R 7 is selected from the group consisting of -OH, -NRi S Ri 6 , alkyl, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, akenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted.
  • R 7 is selected from the group consisting of -OH, -NRi S Ri 6 , alkyl, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, akenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
  • the present invention provides methods and uses which comprise administering compounds of formula of I-d:
  • R' and R" are independently selected from the group consisting of H, halogen, -OH, -NH 2 , -NO 2 , -CN, -CF 3 , -OCF 3 , -N 3 , -SO 3 H, -S(O) 2 alkyl, -S(O)alkyl, -OS(O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino; and wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)
  • R 7 and n are as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • R' is H or OMe
  • R" is H.
  • the present invention provides methods and uses which comprise administering compounds of formula I-d, wherein R 7 is selected from the group consisting of -OH, -NRi 5 Ri 6 , alkyl, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, akenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted.
  • the present invention provides methods and uses which comprise administering compounds of formula of I-e:
  • each R, R 5 , q and n is as defined compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula I-e, wherein R 5 is selected from the group consisting of -NR I 5 R I 6 , -(CH 2 ) Z NR
  • the present invention provides methods and uses which comprise administering compounds of formula I-e, wherein R 5 is an alkyl substituted by at least one labeling group, such as a fluorescent, a bioluminescent, a chemiluminescent, a colorimetric and a radioactive labeling group.
  • R 5 is an alkyl substituted by at least one labeling group, such as a fluorescent, a bioluminescent, a chemiluminescent, a colorimetric and a radioactive labeling group.
  • a fluorescent labeling group can be selected from bodipy, dansyl, fluorescein, rhodamine, Texas red, cyanine dyes, pyrene, coumarins, Cascade BlueTM, Pacific Blue, Marina Blue, Oregon Green, 4',6-Diamidino-2-phenylindole (DAPI), indopyra dyes, lucifer yellow, propidium iodide, porphyrins, arginine, and variants and derivatives thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula of I-f:
  • R 5 and n are as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula I-f, wherein -(CH 2 ) Z NRi 5 Ri 6 , selected from the group consisting of -NR] 5 Ri 6 , -NHOH, -OR) 5 , -CH 2 X, alkyl, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkyl, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted.
  • the present invention provides methods and uses which comprise administering compounds of formula of I-g:
  • W is S or O; each R, Ri 5 , Ri 6 , q, and n is as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula I-g, wherein Rj 5 and Ri 6 independently are selected from the group consisting of H, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkylamino, aryl ' , cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted; and optionally Ri 5 and Ri 6 together with the N to which they are bonded may form a heterocycle which may be substituted.
  • Rj 5 and Ri 6 independently are selected from the group consisting of H, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl,
  • the present invention provides methods and uses which comprise administering compounds of formula I-g, wherein W is O or S.
  • the present invention provides methods and uses which comprise administering compounds of formula of I-h:
  • Ri 5 , Ri 6 and n are as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula I-h, wherein Ri 5 and R] 6 independently are selected from the group consisting of H, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted; and optionally Ri 5 and R] 6 together with the N to which they are bonded may form a heterocycle which may be substituted.
  • the present invention provides methods and uses which comprise administering compounds of formula I-g, wherein W is O or S.
  • the present invention provides methods and uses which comprise administering compounds of formula of I-i:
  • R) 7 is selected from the group consisting Of-NRi S Ri 6 , -NHNRi S Ri 6 , -NHOH, -ORi 5 , -CH 2 X, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; each R, q, and n is as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • the present invention provides methods and uses which comprise administering compounds of formula I-i, wherein each R is independently selected from the group consisting of H, halogen, -OH, OMe, -NH 2 , -NO 2 , -CN, -CF 3 , -OCF 3 , -N 3 , -S(O) 2 C i-C 4 alkyl, -S(O)C r C 4 alkyl, -S-d-C 4 alkyl, -OS(O) 2 CF 3 , Ph, -NHCH 2 Ph, - C(O)Me, -OC(O)Me, morpholinyl and propenyl; and n is O, 1, or 2.
  • the present invention provides methods and uses which comprise administering compounds of formula I-i, wherein R
  • R n is -OH, -OMe, -NEt, -NHEt, -NHPh, -NH 2 , or - NHCH 2 pyridyl.
  • the present invention provides methods and uses which comprise administering compounds of formula of I-j:
  • R' and R" are independently selected from the group consisting of H, halogen, -OH, -NH 2 , -NO 2 , -CN, -CF 3 , -OCF 3 , -N 3 , -SO 3 H, -S(O) 2 alkyl, -S(O)alkyl, -OS(O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino; and wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)
  • R n is selected from the group consisting Of-NRi 5 Ri 6 , -NHNRi 5 Ri 6 , -NHOH, -OR, 5 , -CH 2 X, alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkenyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; n is as defined in compounds of formula I-a; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • R' is H or OMe
  • R" is H.
  • the present invention provides methods and uses which comprise administering compounds of formula I-j, wherein Ri 7 is -NRi 5 Ri 6 or -ORi 5 .
  • R n is -OH, -OMe, -NEt, -NHEt, -NHPh, -NH 2 , or - NHCH 2 pyridyl.
  • the present invention provides methods and uses which comprise administering compounds of formula I-k:
  • the present invention provides methods and uses which comprise administering compounds of formula I-k, wherein R' and R" are independently selected from the group consisting of H, halogen, -OH, OMe, -NH 2 , -NO 2 , - CN, -CF 3 , -OCF 3 , -N 3 , -S(O) 2 C i-C 4 alkyl, -S(O)C r C 4 alkyl, -S-C,-C 4 alkyl, -OS(O) 2 CF 3 , Ph, -NHCH 2 Ph, -C(O)Me, -OC(O)Me, morpholinyl and propenyl; and n is O, 1 or 3.
  • R' is H or OMe
  • R" is H.
  • n is O
  • Rig is Ci-C 4 alkyl, such as Me, Et, propyl, and butyl.
  • m is 2
  • Ri 8 is pyrrolidine, piperidine, piperazine, or morpholine.
  • Ri 8 is a fluorescent labeling group selected from bodipy, dansyl, fluorescein, rhodamine, Texas red, cyanine dyes, pyrene, coumarins, Cascade BlueTM, Pacific Blue, Marina Blue, Oregon Green, 4',6-Diamidino-2-phenylindole (DAPI), indopyra dyes, lucifer yellow, propidium iodide, porphyrins, arginine, and variants and derivatives thereof.
  • DAPI 4',6-Diamidino-2-phenylindole
  • the present invention provides methods and uses which comprise administering compounds of formula of 1-1:
  • R 6 and n are as defined in compounds of formula I-a; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • R' is H or OMe
  • R" is H.
  • the present invention provides methods and uses which comprise administering compounds of formula 1-1, wherein R 6 is selected from the group consisting of -NR, 5 Ri 6 , -NHNR 15 R 16 , -OR 15 , -NHOH, -CH 2 X, acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted.
  • R 6 is -NR
  • R 8 , R 9 and n are as defined in compounds of formula I-a above; and enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, complexes and pro-drugs thereof.
  • R' is H or OMe
  • R" is H.
  • the present invention provides methods and uses which comprise administering compounds of formula I-m, wherein R 8 and R 9 are independently alkyl, aryl, -OH, alkoxyl, or alkylamino.
  • R 8 is Ci-C 4 alkyl such as Me, Et, propyl and butyl; and R 9 is aryl such as phenyl.
  • the present invention provides methods and uses which comprise administering compounds of formula I-n,
  • R d is CH 2 , or NR 3 ;
  • R 3 is H, -(Ci-C 6 alkyl)-aryl, wherein the aryl is a disubstituted phenyl or a benzo[l,3]dioxo-5-yl group, or an amine protecting group (e.g., a Boc group); and
  • R b is hydrogen of alkoxy (e.g., methoxy).
  • Representative compounds of Formula I-n include without limitation SlOl,
  • the invention provides compounds of Formula
  • R e is -(Ci-C 6 alkyl)-phenyl, -(Ci-C 6 alkyl)-C(O)R t> , or substituted or unsubstituted - C-C 6 alkyl;
  • R b is -OH or -0-(Ci-C 6 alkyl), and wherein the phenyl or substituted alkyl is substituted with one or more of halogen, hydroxyl, -C-C 6 alkyl, -0-(Ci-C 6 alkyl), -NH 2 , -NH(Ci-C 6 alkyl), -N(C 1 -C 6 alkyl) 2 , cyano, or dioxolane.
  • Representative compounds of Formula I-o include without limitation S 107,
  • the invention provides compounds of Formula
  • R c is -(C-C 6 alkyl)-NH 2 , -(C,-C 6 alkyl)-OR f , wherein R f is H or -C(O)-(C ,-C 6 )alkyl, Or -(Ci-C 6 alkyl)-NHR g wherein Rg is carboxybenzyl.
  • Representative compound of Formula I-p include without limitation S 109, S 122, S 123.
  • Formulae-la, Ib, Ie, If, Ig, Ih, In are represented by compounds SlOl, S 102, S 103.
  • Formulae Ia, Ib, Ie, If, Ii, Ij are represented by compound S 104.
  • Formulae Ia, Ib, Io are represented by S 107.
  • Formulae Ia, Ib, Ie, If are represented by S 108.
  • Formulae Ia, Ib, Ie, If, Ip are represented by S 109.
  • Formulae Ia, Ib, Ik, Io are represented by Sl 10.
  • Formulae Ia, Ib, Ik, Io are represented by S 111.
  • Formulae Ia, Ib, Ic, Id are represented by Sl 12.
  • Formulae Ia, Ib are represented by Sl 13.
  • Formulae Ia, Ib, Ie, If, Ig, Ih are represented by Sl 14.
  • Formulae Ia, Ib, Ig, Ih, Il are represented by Sl 15.
  • Formulae Ia, Ib, Ig, Ih, are represented by Sl 16.
  • Formulae Ia, Ib, Ie, If are represented by Sl 17.
  • Formulae Ia, Ib, Ie, If are represented by Sl 18.
  • Ia, Ib are represented by Sl 19.
  • Formulae Ia, Ib, Ik, Io are represented by S 120.
  • Formulae Ia, Ib, Ik, Io, Ip are represented by S 121.
  • Formulae Ia, Ib, Ie, If, Ip are represented by S 122.
  • Formulae Ia, Ib, Ie, If, Ip are represented by S 123.
  • I-m, I-n, I-o, and I-p, and Formula II can be used in methods that treat or prevent disorders and diseases associated with the RyR receptors.
  • examples of such compounds include, without limitation, Sl, S2, S3, S4, S5,
  • the compound is not S4. In another embodiment, the compound is not S7. In another embodiment, the compound is not S8. In another embodiment, the compound is not SlO. In another embodiment, the compound is not S20. In another embodiment, the compound is not S24. In another embodiment, the compound is not S25. In another embodiment, the compound is not S26. In another embodiment, the compound is not S27. In another embodiment, the compound is not S36. In another embodiment, the compound is not JTV-519.
  • each R is independently selected from the group consisting of H, halogen, -OH, -NH 2 , -NO 2 , -CN, -N 3 , -SO 3 H, acyl, alkyl, alkylamino, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, (hetero-)aryl, (hetero-)arylthio, and (hetero- )arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino may be substituted with one or more radicals independently selected from the group consisting of halogen, N, O, -S-, -CN, -N 3
  • each R is independently selected from the group consisting of H, halogen, -OH, -NH 2 , -NO 2 , -CN, -N 3 , -SO 3 H, acyl, alkyl, alkylamino, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, (hetero- )aryl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, (hetero-)aryl, (hetero- )arylthio, and (hetero-)arylamino may be substituted with one or more radicals independently selected from the group consisting of halogen, N, O, -S-, -CN, -N 3 , -SH, nitro, ox
  • R 5 is selected from the group consisting of -NRi 6 , -(CH 2 ) z NRi 5 Ri 6 , NHNHR )6 , NHOH, -ORi 5 , CONH 2 NHRi 6 , CONR 16 , CH 2 X, acyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted with one or more radicals independently selected from the group consisting of halogen, N, O, -S-, -CN, -N 3 , nitro, oxo, acyl, alkyl, alkoxyl, alkylamino, alkenyl, aryl, (hetero-)cycloalkyl, and (heter
  • the present invention provides use of compounds of
  • Formula II is discussed also in co-pending application 10/680,988, the disclosure of which is incorporated herein in its entirety by reference.
  • the compounds of the invention reduce the open probability of RyR by increasing the affinity of FKBP 12 (calstabinl) and FKBP 12.6 (calstabin2) for, respectively PKA-phosphorylated RyRl and PKA-phosphorylated RyR2.
  • the compounds of Formula I normalize gating of mutant RyR channels, including CPVT-associated mutant RyR2 channels, by increasing FKBP 12 (calstabinl) and FKBP 12.6 (calstabin2) binding affinity. Therefore, the compounds of the invention prevent disorders and conditions involving modulation of the RyR receptors, particularly the RyRl and RyR2 receptors.
  • Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise- induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
  • Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof.
  • Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence.
  • Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
  • the present invention provides a method for limiting or preventing a decrease in the level of RyR-bound FKBP (calstabin) in cells of a subject.
  • RyR includes RyRl, RyR2, and RyR3.
  • FKBP includes both FKBP12 (calstabinl) and FKBP12.6 (calstabin2).
  • RyR-bound FKBP therefore refers to RyRl-bound FKBP12 (calstabinl), RyR2-bound FKBP12.6 (calstabin2), and RyR3-bound FKBP12 (calstabinl).
  • RyR also includes an “RyR protein” and an “RyR analogue.”
  • RyR analogue is a functional variant of the RyR protein, having RyR biological activity, that has 60% or greater amino-acid-sequence homology with the RyR protein.
  • the RyR of the present invention are unphosphorylated, phosphorylated (e.g., by PKA), or hyperphosphorylated (e.g., by PKA).
  • RyR biological activity refers to the activity of a protein or peptide that demonstrates an ability to associate physically with, or bind with, FKBP12 (calstabinl) in the case of RyRl and RyR3, and FKBP12.6 (calstabin2) in the case of RyR2 (i.e., binding of approximately two fold or, approximately five fold, above the background binding of a negative control), under the conditions of the assays described herein.
  • FKBP includes both an “FKBP protein” and an “FKBP analogue,” whether it be FKBP 12 (calstabinl) or FKBP 12.6 (calstabin2).
  • protein shall include a protein, protein domain, polypeptide, or peptide, and any fragment thereof.
  • An "FKBP analogue” is a functional variant of the FKBP protein, having FKBP biological activity, that has 60% or greater amino-acid-sequence homology with the FKBP protein, whether it be FKBP12 (calstabinl) or FKBP12.6 (calstabin2).
  • FKBP biological activity refers to the activity of a protein or peptide that demonstrates an ability to associate physically with, or bind with, unphosphorylated or non-hyperphosphorylated Ry R2 (i.e., binding of approximately two fold, or approximately five fold, above the background binding of a negative control), under the conditions of the assays described herein.
  • RyR-bound FKBP includes a molecule of an FKBP 12 (calstabinl) protein that is bound to an RyRl protein subunit or a tetramer of FKBP 12 that is in association with a tetramer of RyRl, a molecule of FKBP 12.6 (calstabin2) protein that is bound to an RyR2 protein subunit or a tetramer of FKBP12.6 that is in association with a tetramer of RyR2, and a molecule of an FKBP 12 (calstabinl) protein that is bound to an RyR3 protein subunit or a tetramer of FKBP 12 that is in association with a tetramer of RyR3. Therefore, "RyR-bound FKBP” refers to "RyRl -bound FKBP 12," "RyR2-bound F
  • disorder in the level of RyR-bound FKBP in cells of a subject refers to a detectable decrease, diminution or reduction in the level of RyR-bound FKBP in cells of the subject. Such a decrease is limited or prevented in cells of a subject when the decrease is in any way halted, hindered, impeded, obstructed or reduced by the administration of compounds of the invention, such that the level of RyR-bound FKBP in cells of the subject is higher than it would otherwise be in the absence of the administered compound.
  • the level of RyR-bound FKBP in a subject is detected by standard assays and techniques, including those readily determined from the known art (e.g., immunological techniques, hybridization analysis, immunoprecipitation, Western-blot analysis, fluorescence imaging techniques and/or radiation detection, etc.), as well as any assays and detection methods disclosed herein.
  • standard assays and techniques including those readily determined from the known art (e.g., immunological techniques, hybridization analysis, immunoprecipitation, Western-blot analysis, fluorescence imaging techniques and/or radiation detection, etc.), as well as any assays and detection methods disclosed herein.
  • protein is isolated and purified from cells of a subject using standard methods known in the art, including, without limitation, extraction from the cells (e.g., with a detergent that solubilizes the protein) where necessary, followed by affinity purification on a column, chromatography (e.g., FTLC and HPLC), immunoprecipitation (with an antibody), and precipitation (e.g., with isopropanol and a reagent such as Trizol). Isolation and purification of the protein is followed by electrophoresis (e.g., on an SDS-polyacrylamide gel).
  • a decrease in the level of RyR-bound FKBP in a subject, or the limiting or prevention thereof, is determined by comparing the amount of RyR-bound FKBP detected prior to the administration of a compound of the invention I (in accordance with methods described below) with the amount detected a suitable time after administration of the compound.
  • a decrease in the level of RyR-bound FKBP in cells of a subject is limited or prevented, for example, by inhibiting dissociation of FKBP and RyR in cells of the subject; by increasing binding between FKBP and RyR in cells of the subject; or by stabilizing the RyR-FKBP complex in cells of a subject.
  • a decrease in the level of RyR-bound FKBP in cells of a subject is limited or prevented by directly decreasing the level of phosphorylated RyR in cells of the subject or by indirectly decreasing the level of phosphorylated RyR in the cells (e.g., by targeting an enzyme (such as PKA) or another endogenous molecule that regulates or modulates the functions or levels of phosphorylated RyR in the cells).
  • the level of phosphorylated RyR in the cells is decreased by at least 10% in the method of the present invention. In another embodiment, the level of phosphorylated RyR is decreased by at least 20%.
  • the subject of the present invention are in vitro and in vivo systems, including, without limitation, isolated or cultured cells or tissues, non-cell in vitro assay systems and an animal (e.g., an amphibian, a bird, a fish, a mammal, a marsupial, a human, a domestic animal (such as a cat, dog, monkey, horse, mouse or rat) or a commercial animal (such as a cow or pig)).
  • an animal e.g., an amphibian, a bird, a fish, a mammal, a marsupial, a human, a domestic animal (such as a cat, dog, monkey, horse, mouse or rat) or a commercial animal (such as a cow or pig)).
  • the cells of a subject include striated muscle cells.
  • a striated muscle is a muscle in which the repeating units (sarcomeres) of the contractile myofibrils are arranged in registry throughout the cell, resulting in transverse or oblique striations that are observed at the level of a light microscope.
  • Examples of striated muscle cells include, without limitation, voluntary (skeletal) muscle cells and cardiac muscle cells.
  • the cell used in the method of the present invention is a human cardiac muscle cell.
  • the term "cardiac muscle cell” includes cardiac muscle fibers, such as those found in the myocardium of the heart.
  • Cardiac muscle fibers are composed of chains of contiguous heart- muscle cells, or cardiomyocytes, joined end to end at intercalated disks. These disks possess two kinds of cell junctions: expanded desmosomes extending along their transverse portions, and gap junctions, the largest of which lie along their longitudinal portions.
  • a decrease in the level of RyR-bound FKBP is limited or prevented in cells of a subject by administering the compounds of the invention to the subject; this would also permit contact between cells of the subject and the compounds of the invention.
  • the compounds of the invention are modulators of calcium-ion channels. In addition to regulating Ca 2+ levels in myocardial cells, the compounds of the invention modulate the Na + current and the inward-rectifier K + current in cells, such as guinea pig ventricular cells, and inhibits the delayed-rectifier K + current in cells, such as guinea pig atrial cells.
  • compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo.
  • the present invention provides a pharmaceutical composition comprising compounds of the invention in admixture with a pharmaceutically acceptable diluent and/or carrier.
  • the pharmaceutically-acceptable carrier must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
  • the pharmaceutically-acceptable carrier employed herein is selected from various organic or inorganic materials that are used as materials for pharmaceutical formulations and which are incorporated as analgesic agents, buffers, binders, disintegrants, diluents, emulsifiers, excipients, extenders, glidants, solubilizers, stabilizers, suspending agents, tonicity agents, vehicles and viscosity-increasing agents.
  • pharmaceutical additives such as aromatics, colorants, flavor- improving agents, preservatives, and sweeteners, are also added.
  • acceptable pharmaceutical carriers include carboxymethyl cellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methyl cellulose, powders, saline, sodium alginate, sucrose, starch, talc and water, among others.
  • the pharmaceutical formulations of the present invention are prepared by methods well-known in the pharmaceutical arts.
  • the compounds of the invention are brought into association with a carrier and/or diluent, as a suspension or solution.
  • a carrier and/or diluent as a suspension or solution.
  • one or more accessory ingredients e.g., buffers, flavoring agents, surface active agents, and the like.
  • the choice of carrier is determined by the solubility and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.
  • the compounds of the invention are administered to a subject by contacting target cells (e.g., cardiac muscle cells) in vivo in the subject with the compounds.
  • target cells e.g., cardiac muscle cells
  • the compounds of the invention are contacted with (e.g., introduced into) cells of the subject using known techniques utilized for the introduction and administration of proteins, nucleic acids and other drugs.
  • methods for contacting the cells with (i.e., treating the cells with) the compounds of the invention include, without limitation, absorption, electroporation, immersion, injection, introduction, liposome delivery, transfection, transfusion, vectors and other drug-delivery vehicles and methods.
  • the target cells are localized to a particular portion of a subject, it is desirable to introduce the compounds for the invention directly to the cells, by injection or by some other means (e.g., by introducing the compounds into the blood or another body fluid).
  • the target cells are contained in tissue of a subject and are detected by standard detection methods readily determined from the known art, examples of which include, without limitation, immunological techniques (e.g., immunohistochemical staining), fluorescence imaging techniques, and microscopic techniques.
  • the compounds of the present invention are administered to a human or animal subject by known procedures including, without limitation, oral administration, sublingual or buccal administration, parenteral administration, transdermal administration, via inhalation or intranasally, vaginally, rectally, and intramuscularly.
  • the compounds of the invention are administered parenterally, by epifascial, intracapsular, intracranial, intracutaneous, intrathecal, intramuscular, intraorbital, intraperitoneal, intraspinal, intrasternal, intravascular, intravenous, parenchymatous, subcutaneous or sublingual injection, or by way of catheter.
  • the agent is adiminstered to the subject by way of delivery to the subject's muscles including, but not limited to, the subject's cardiac muscles.
  • the agent is administered to the subject by way of targeted delivery to cardiac muscle cells via a catheter inserted into the subject's heart. In other embodiments, the agent is administered via a subcutaneous pump.
  • a formulation of the compounds of the invention are presented as capsules, tablets, powders, granules or as a suspension or solution.
  • the formulation has conventional additives, such as lactose, mannitol, corn starch or potato starch.
  • the formulation also is presented with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins.
  • the formulation is presented with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose.
  • the formulation also is presented with dibasic calcium phosphate anhydrous or sodium starch glycolate.
  • lubricants such as talc or magnesium stearate.
  • the compounds of the invention are combined with a sterile aqueous solution that is isotonic with the blood of the subject.
  • a sterile aqueous solution that is isotonic with the blood of the subject.
  • a formulation is prepared by dissolving a solid active ingredient in water containing physiologically-compatible substances, such as sodium chloride, glycine and the like, and having a buffered pH compatible with physiological conditions, so as to produce an aqueous solution, then rendering said solution sterile.
  • the formulation is presented in unit or multi-dose containers, such as sealed ampoules or vials.
  • the formulation is delivered by any mode of injection, including, without limitation, epifascial, intracapsular, intracranial, intracutaneous, intrathecal, intramuscular, intraorbital, intraperitoneal, intraspinal, intrasternal, intravascular, intravenous, parenchymatous, subcutaneous, or sublingual or by way of catheter into the subject's heart.
  • the compounds of the invention are combined with skin penetration enhancers, such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone and the like, which increase the permeability of the skin to the compounds of the invention and permit the compounds to penetrate through the skin and into the bloodstream.
  • skin penetration enhancers such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone and the like, which increase the permeability of the skin to the compounds of the invention and permit the compounds to penetrate through the skin and into the bloodstream.
  • the compounds of the invention /enhancer composition also are further combined with a polymeric substance, such as ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like, to provide the composition in gel form, which are dissolved in a solvent, such as methylene chloride, evaporated to the desired viscosity and then applied to backing material to provide a patch.
  • a polymeric substance such as ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate, polyvinyl pyrrolidone, and the like
  • the composition is in unit dose form such as a tablet, capsule or single-dose vial.
  • Suitable unit doses i.e., therapeutically effective amounts, can be determined during clinical trials designed appropriately for each of the conditions for which administration of a chosen compound is indicated and will, of course, vary depending on the desired clinical endpoint.
  • the present invention also provides articles of manufacture for treating and preventing disorders, such as cardiac disorders, in a subject.
  • the articles of manufacture comprise a pharmaceutical composition of one or more of the compounds of the invention as described herein.
  • the articles of manufacture are packaged with indications for various disorders that the pharmaceutical compositions are capable of treating and/or preventing.
  • the articles of manufacture comprise a unit dose of a compound disclosed herein that is capable of treating or preventing a muscular disorder, and an indication that the unit dose is capable of treating or preventing a certain disorder, for example an arrhythmia.
  • the compounds of the invention are administered to the subject (or are contacted with cells of the subject) in an amount effective to limit or prevent a decrease in the level of RyR-bound FKBP in the subject, particularly in cells of the subject. This amount is readily determined by the skilled artisan, based upon known procedures, including analysis of titration curves established in vivo and methods and assays disclosed herein.
  • a suitable amount of the compounds of the invention effective to limit or prevent a decrease in the level of RyR-bound FKBP in the subject ranges from about 5 mg/kg/day to about 20 mg/kg/day, and/or is an amount sufficient to achieve plasma levels ranging from about 300 ng/ml to about 1000 ng/ml. In an embodiment, the amount of compounds from the invention ranges from about 10 mg/kg/day to about 20 mg/kg/day.
  • the present invention provides a new range of therapeutic treatments for patients with various disorders involving modulation of the RyR receptors, particularly skeletal muscular disorders (RyRl).
  • the present application also provides new therapeutic treatment strategies for patients with muscle fatigue resulting from various disease states and dis Arthurs that are assocdiated with RyR, including, but not limited to cardiac (RyR2) disorders, and/or cognitive (RyR3) disorders.
  • the subject has not yet developed symptoms of muscle fatigue, (e.g., exercise-induced muscle fatigue).
  • the subject is in need of treatment for a disorder associated with muscle fatigue, including skeletal muscular disorders.
  • Various disorders that the compounds of the invention treat or prevent include, but are not limited to, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome.
  • Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
  • Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof.
  • Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence.
  • Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
  • One skilled in the art will recognize still other diseases, including but not limited to muscular and cardiac disorders, that the compounds of the invention are useful to treat, in accordance with the information provided herein.
  • the amount of compounds of the invention effective to limit or prevent a decrease in the level of RyRl -bound FKBP 12 in the subject is an amount effective to prevent muscle fatigue in the subject. This amount is readily determined by the skilled artisan, based upon known procedures, including clinical trials, and methods disclosed herein.
  • the compounds of the invention are also useful in treating a subject who has already experienced clinical symptoms of these various disorders. For example, if the symptoms of the disorder are observed in the subject early enough, the compounds of the invention are effective in limiting or preventing a further decrease in the level of RyR-bound FKBP in the subject.
  • the subject of the present invention can be a candidate for muscle fatigue disorder, including but not limited to any chronic disorder associated with muscle fatigue, or stress or exercise-induced muscle fatigue.
  • the subject has been exercising, or is currently exercising, and has developed an exercise-induced disorder.
  • the amount of the compounds of the invention effective to limit or prevent a decrease in the level of RyR-bound FKBP in the subject is an amount of compound effective to treat the exercise-induced disorder in the subject.
  • an amount of compounds of the invention "effective to treat an exercise-induced disorder" includes an amount of compound of the invention effective to alleviate or ameliorate the clinical impairment or symptoms of the exercise-induced disorder characterized by muscle fatigue.
  • the amount of compounds of the invention effective to treat an exercise-induced disorder in a subject will vary depending upon the particular factors of each case, including the type of exercise-induced disorder, the subject's weight, the severity of the subject's condition, and the mode of administration of the compounds of the invention. This amount is readily determined by the skilled artisan, based upon known procedures, including clinical trials, and methods disclosed herein.
  • the compounds of the invention treat exercise- induced disorders in the subject.
  • the present invention further provides a method for treating muscle fatigue associated with exercise-induced disorders and conditions in a subject.
  • the method comprises administering the compounds of the invention to the subject in an amount effective to treat the exercise-induced disorder in the subject.
  • a suitable amount of the compounds of the invention effective to treat, for example, exercise-induced cardiac arrhythmia in the subject ranges from about 5 mg/kg/day to about 20 mg/kg/day, and/or is an amount sufficient to achieve plasma levels ranging from about 300 ng/ml to about 1000 ng/ml.
  • the present invention also provides a method for preventing an exercise-induced disorder in a subject. The method comprises administering the compounds of the invention to the subject in an amount effective to prevent the exercise-induced disorder in the subject.
  • a suitable amount of the compounds of the invention effective to prevent the exercise-induced disorder in the subject ranges from about 5 mg/kg/day to about 20 mg/kg/day, and/or is an amount sufficient to achieve plasma levels ranging from about 300 ng/ml to about 1000 ng/ml.
  • the present invention provides a method for preventing exercise-induced disorders in a subject. The method comprises administering the compounds of the invention to the subject in an amount effective to prevent an exercise-induced disorder in the subject.
  • a suitable amount of the compounds of the invention effective to prevent an exercise-induced disorder in the subject ranges from about 5 mg/kg/day to about 20 mg/kg/day, and/or is an amount sufficient to achieve plasma levels ranging from about 300 ng/ml to about 1000 ng/ml.
  • the compounds of the invention can be used alone, in combination with each other, or in combination with other agents that have cardiovascular activity including, but not limited to, diuretics, anticoagulants, antiplatelet agents, antiarrhythmics, inotropic agents, chronotropic agents, ⁇ and ⁇ blockers, angiotensin inhibitors and vasodilators. Further, such combinations of the compounds of the present invention and other cardiovascular agents are administered separately or in conjunction. In addition, the administration of one element of the combination is prior to, concurrent to or subsequent to the administration of other agent(s).
  • the present invention also provides use of the compounds of the invention in a method for limiting or preventing a decrease in the level of RyR-bound FKBP in a subject who is a candidate for a disorder.
  • the present invention also provides use of the compounds of the invention in a method for treating or preventing a muscular disorder in a subject.
  • the present invention provides use of the compounds of the invention in a method for preventing treating or preventing exercise- induced muscular disorders in a subject.
  • Intracellular Ca 2+ leak is proposed as a principal mediator of depressed muscle performance and dystrophic muscle remodeling.
  • Muscular dystrophies are heterogeneous hereditary diseases characterized by weakness and progressive muscle wasting.
  • dystrophinopathies Duchenne muscular dystrophy (DMD) is one of the most frequent genetic diseases (X-linked; 1 in 3,500 boys) with death usually occurring before age 30 by respiratory and/or cardiac failure in high numbers of patients.
  • Becker muscular dystrophy represents a milder form of the disease associated with a reduction in the amount or expression of a truncated form of the dystrophin protein whereas Duchenne patients have been characterized by complete absence or very low levels of dystrophin.
  • Duchenne and Becker's muscular dystrophy are caused by mutations in the gene encoding the 427-kDa cytoskeletal protein dystrophin.
  • cardiac symptoms are more common than in DMD patients and do not correlate with skeletal muscle symptoms. Since genetic screening will not eliminative DMD due to a high incidence of sporadic cases, an effective therapy is highly desirable.
  • DMD/BMD have been consistently associated with disturbed intracellular calcium metabolism. Because alterations of intracellular Ca 2+ concentrations in DMD myofibers are believed to represent a central pathogenic mechanism, development of a therapeutic intervention that prevents intracellular Ca 2+ abnormalities as a cause of skeletal muscle degeneration is highly desirable.
  • the compounds of the present invention are prepared in different forms, such as salts, hydrates, solvates, complexes, pro-drugs or salts of pro-drugs and the invention includes all variant forms of the compounds.
  • the present invention further provides a composition, comprising radio labeled compounds of the invention. Labeling of the compounds of the invention is accomplished using one of a variety of different radioactive labels known in the art.
  • the radioactive label of the present invention is, for example, a radioisotope.
  • the radioisotope is any isotope that emits detectable radiation including, without limitation, 35 S, 125 1, 3 H, or 14 C. Radioactivity emitted by the radioisotope can be detected by techniques well known in the art. For example, gamma emission from the radioisotope is detected using gamma imaging techniques, particularly scintigraphic imaging.
  • radio-labeled compounds of the invention are prepared as follows. A compound of the invention is demethylated at the phenyl ring using BBr 3 . The resulting phenol compound then is re-methylated with a radio-labeled methylating agent (such as 3 H-dimethyl sulfate) in the presence of a base (such as NaH) to provide 3 H-labeled compounds.
  • a radio-labeled methylating agent such as 3 H-dimethyl sulfate
  • a base such as NaH
  • RyRl channels are PKA hyperphosphorylated and depleted of the stabilizing calstabinl subunit after 3 weeks of 90 mins swimming twice daily.
  • the immunoprecipitated RyRl macromolecular channel complex shows increased PKA phosphorylation at Ser-2844 (corresponding to human RyRl -Ser-2843) whereas CaMKII phosphorylation at Ser-2849 (corresponding to human RyRl-Ser-2848) is unchanged.
  • Concomitant with increased RyRl- Ser-2844 PKA hyperphosphorylation calstabinl is depleted from the channel complex. Normalization of phosphorylation and calstabinl content to four subunits of the tetrameric channel complex shows a significant in increase in PKA phosphorylation and depletion of the stabilizing calstabinl subunit.
  • the RyCaI compounds referred to as S36, S 107 were synthesized as described in co-pending applications USSN 11/212,309 and PCT/US2006/32405.
  • Figures 1-6 show some aspects of the molecular mechanisms which lead to muscle fatigue and the effect of S36 on muscle fatigue.
  • mice were exercised for three weeks by swimming 5 days/week and by running on a treadmill an additional 1 day/week.
  • swimming Model The daily swimming protocol consisted of swimming sessions twice-daily separated by one-hour rest periods. After an initial conditioning regimen lasting 5 days during which the swimming sessions were increased in 10 minute increments from 40 minutes each to 80 minutes each, the swimming sessions thereafter lasted 90 minutes each.
  • a 30 cm wide by 30 cm long opaque acrylic tank was filled with tap water to a depth of at least 20 cm. Water was circulated and warmed to 32-34 degrees C using a separate reservoir with heating element, thermostat, and pump. Compressed room air was bubbled from Tygon tubing with small needle holes placed at the bottom of the tank to agitate the water surface. 4 mice, matched pair-wise with respect to treatment group, swam at any one time in the tank. Littermates who did not exercise were reserved as negative controls.
  • mice were placed in their respective lanes at the lowest speed (7 meters/min) with the shocking apparatus turned off and allowed to adjust to the surroundings for 6 minutes.
  • the forward half of the treadmill was covered with aluminum foil to block out light.
  • a desk lamp illuminated the shocking area at the rear of the treadmill.
  • the electric current was turned on, and the number of shocks delivered during the next two three minute intervals(training period) were recorded.
  • the shock counter was then reset, the speed was increased to 10 m/min, and visits to the shocking area and shocks delivered to each mouse were recorded at three-minute intervals until the end of the experiment.
  • the speed of the treadmill was ramped up from the initial 10 m/min to as high as 36 m/min. The speed was increased no more than 2 m/min every 6 minutes. Consistent treadmill speed increases were used for all mice on a given day, but the protocol increased in difficulty over the course of the 21 day experiment. Task failure was defined when a mouse could not continue running to avoid the shocking area and gave up or when the mouse had received 200 cumulative shocks. In nearly all cases, these two times were very close to identical.
  • mice were swum a final time on a staggered schedule. Following 90 minutes of swimming, each mouse was immediately sacrificed by carbon dioxide inhalation and cervical dislocation. Blood was removed by intracardiac aspiration, spun down, and plasma was eluted and frozen in liquid nitrogen. Both extensor digitorum longus (EDL) muscles were exposed, moistened with Tyrode's solution, and 4-0 silk sutures were tied to the proximal and distal tendons and the muscles were dissected free.
  • EDL extensor digitorum longus
  • the muscles were perfused with Tyrode's solution containing 2.0 mM CaCl 2 , bubbled with 100% O 2 , warmed to 35 C, and hung on isometric force transducers(F-30, Harvard Apparatus, Cambridge, MA). After equilibration for 10 minutes at a resting tension of 1 cN and a brief potentiation protocol, force-frequency relationships were measured, with 60 second delays between 800 ms stimulations at 40-150 Hz. Fatigue was produced with a protocol of 50 Hz tetani (each 600 ms long) every 2 seconds for 120 seconds. DMC v4.1.6 (Aurora Scientific, Canada) was used to stimulate and record muscle responses, and DMA v3.2(Aurora Scientific, Canada) was used to analyze the resultant data.
  • both soleus muscles were dissected and likewise one was frozen in isopentane for histology and one was frozen in liquid N 2 for biochemical analysis.
  • the vastus lateralis, heart, and diaphragm were also dissected from each animal and frozen in liquid N 2 for biochemical analysis.
  • RyR channels were immunoprecipitated from skeletal muscle homogenates with anti-RyR antibody in 0.5 ml of buffer (50 mM Tris HCl buffer, pH 7.4 0.9% NaCl 5.0 mM NaF 1.0 mM Na3VO4 0.5% Triton X-100 + protease inhibitors) for 1 hour at 4°C.
  • the samples were incubated with protein A Sepharose beads (Amersham Pharmacia) at 4 0 C for 1 h, after which the beads were washed three times with buffer.
  • Proteins were separated on SDS PAGE gels (6% for RyR2 and 15% for calstabin2) and transferred onto nitrocellulose membranes overnight (SemiDry transfer blot, Bio-Rad). After incubation with 5% nonfat milk to prevent non-specific antibody binding and a wash in Tris- buffered saline with 0.1% Tween-20, membranes were incubated for 1-2 h at room temperature with primary antibodies anti-calstabin(l : 1,000), anti-RyR (5029; 1 :5,000), or anti-phospho-RyR2-pSer2809 (1 :5,000), which detects PKA-phosphorylated mouse RyRl- pSer2844 and RyR2-pSer2808.
  • Figures 7-20 show molecular mechanisms of muscle fatigue and the effect of S107.
  • Chronic Exercise Model The daily swimming protocol consisted of twice- daily swimming sessions separated by a one-hour rest period. After an initial conditioning regimen lasting 5 days during which the swimming sessions were increased in 10 minute increments from 40 minutes each to 80 minutes each, the swimming sessions thereafter lasted 90 minutes each. A 30 cm wide by 30 cm long opaque acrylic tank was filled with tap water to a depth of at least 20 cm. Water was circulated and warmed to 32-34 degrees C using a separate reservoir with heating element, thermostat, and pump. 8 mice, balanced pair-wise with respect to genotype and/or treatment group, swam at any one time in the tank. Littermates who did not exercise were reserved as sedentary controls.
  • Treadmill performance A Columbus Instruments (Columbus, OH) treadmill
  • mice (Model: Exer-6M Treadmill with Treadmill Shock Detection Unit) with 6 lanes was used to run the mice. Mice were placed in their respective lanes with the shocking apparatus turned off and allowed to adjust to the surroundings for 10 minutes. The forward half of the treadmill was covered with aluminum foil to block out light and a desk lamp illuminated the shocking area at the rear of the treadmill. After the adjustment period, the treadmill was set to 10 meters/min, and the mice were trained to run with gentle prodding for 6 minutes. The electric current was then turned on, and the number of shocks delivered during the next two three minute intervals (training period) were recorded. The shock counter was then reset and visits to the shocking area and shocks delivered to each mouse were recorded at three-minute intervals until the end of the experiment.
  • the speed of the treadmill was ramped up from the initial 10 m/min to 24 m/min.
  • the speed was increased no more than 2 m/min every 6 minutes.
  • Task failure was defined when a mouse could not continue running despite gentle prodding.
  • Intact muscle preparation Immediately following a forced exercise session, each mouse was sacrificed by carbon dioxide inhalation and cervical dislocation. Blood was removed by intracardiac aspiration, spun down, and plasma was eluted and frozen in liquid nitrogen. 4-0 silk sutures were tied to the proximal and distal tendons of intact EDL and soleus muscles and the muscles were dissected free and placed in a modified Ringer's solution(140 mM NaCl, 5 mM KcI, 2.0 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, pH 7.4) bubbled with 100% O 2 .
  • a modified Ringer's solution 140 mM NaCl, 5 mM KcI, 2.0 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, pH 7.4
  • Muscles were hung vertically in 50 mL Radnoti jacketed glass chambers with one tendon attached with 4-0 silk suture to an isometric force transducer (F30, Harvard Apparatus, Cambridge, MA) and the other tendon attached by suture to a stationary arm with built in platinum stimulating plate electrodes. After perfusion with 35C Ringer's and equilibration for 10 minutes at a resting tension of 1 cN and a brief potentiation protocol, force-frequency relationships were measured, with 60 second delays between 800 ms stimulations at 40-150 Hz. DMCv4.1.6 (Aurora Scientific, Canada) was used to stimulate and record muscle responses, and DMA v3.2(Aurora Scientific, Canada) was used to analyze the resultant data.
  • isometric force transducer F30, Harvard Apparatus, Cambridge, MA
  • Single fibers were collected and allowed to attach to glass coverslips coated in laminin (Sigma L-2020).
  • the cells were loaded with 2 ⁇ M fluo4-AM ester (Invitrogen) for 20 minutes, placed on the Zeiss Live 5 microscope stage and superfused for 15 minutes with Ringer's.
  • the fibers were paced at 1 Hz for 10 minutes prior to imaging baseline fiber properties.
  • Linescan images were continuously acquired at 1 ms scan rate during a tetanic sequence consisting of 300 ms stimulation at 100 Hz with a 2 Hz train rate. Images were analyzed in ImageJ, and an F/F0 ratio was calculated for each fiber.
  • Planar lipid bilayers were formed across a 200 ⁇ m aperture in a polysulfonate cup (Warner Instruments, Inc.), which separated two bathing solutions (1 mM EGTA, 250/125 mM HEPES/Tris, 50 mM KCl, 0.5 mM CaCl 2 , pH 7.35 as cis solution and 53 mM Ba(OH) 2 , 50 mM KCl, 250 mM HEPES, pH 7.35 as trans solution). After incorporation, RyRl channel activity was recorded continuously for at least 10 minutes. The concentration of free Ca 2+ in the cis chamber was calculated with WinMaxC program (version 2.50) (Bers, Patton et al. 1994).
  • ryanodine receptor (RyRl) was immunoprecipitated by incubating 250 ⁇ g of homogenate with anti-RyR antibody (2 ⁇ l 5029 Ab) in 0.5 ml of a modified RIPA buffer (50 mM Tris-HCl pH 7.4, 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na 3 VO 4 , 0.5% Triton- XlOO, and protease inhibitors) for 1 hr at 4°C.
  • a modified RIPA buffer 50 mM Tris-HCl pH 7.4, 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na 3 VO 4 , 0.5% Triton- XlOO, and protease inhibitors
  • Plasma samples (duplicates, 5 ⁇ l each) were added to 200 ⁇ l of CK reagent and the change in absorbance at 340 nM was recorded over 4 minutes using a plate reader. The average absorbance change per minute was used to determine the CPK levels as per manufacturer's instructions.
  • High intensity exercise induces RyRl PKA hyperphosphorylation, and depletion of calstabinl and PDE4D3 from the channel complex:
  • Exercise models in the mouse have been grouped into two categories: 1) voluntary exercise including running wheels; and 2) involuntary exercise, including swimming or forced treadmill runs to exhaustion.
  • a twice daily swimming protocol was adapted to achieve uniform exercise in mice over days to weeks. This mouse exercise protocol was not designed to be either explicitly eccentric or isometric in character, but rather a physiologic mix of eccentric and isometric exercise.
  • RyRl was immunoprecipitated out of whole muscle homogenates from hind limb muscles, and the RyRl channel complex was size-fractionated on SDS-PAGE and immunoblotted for channel complex components.
  • High-intensity exercise in the mouse resulted in progressive phosphorylation of RyRl at the PKA site Ser2844 (RyRl -pS2844) that saturated by 14 days of twice daily swimming (90 min sessions, e.g. Fig. 8A).
  • the RyRl macromolecular complex from extensor digitorum longus (EDL) muscle underwent remodeling, including depletion of calstabinl and PDE4D3 from the channel by day 14 (Fig. 8 A and 8B).
  • An identical pattern of biochemical changes was seen in all other hind limb skeletal muscles isolated from the same mice, including soleus, tibialis anterior, and gastrocnemius.
  • RyRl PKA hyperphosphorylation and depletion of calstabinl and PDE4D3 were dependent on the intensity of the exercise, with only relatively high intensity exercise resulting in significant channel modifications (Fig 8C and 8D).
  • RyRl channel defects occur during human exercise: To assess whether the remodeling of the RyRl channel macromolecular complex observed in exercised mice is relevant to human physiology, human thigh muscle biopsies were obtained from trained athletes before and after exercise on Days 1 and 3 of a high-intensity exercise protocol (cycling 3 hr/day at 57% of V0 2 max)(Nieman, Henson et al. 2006). The human RyRl macromolecular complex was immunoprecipitated from muscle homogenate, size fractionated by SDS-PAGE, and immunoblotted to assess RyRl PKA phosphorylation and levels of calstabinl and PDE4D3 in the RyRl complex.
  • Muscle-specific deficiency of calstabinl has been previously shown to be associated with alterations in the force-frequency relationships of isolated muscle preparations and a reduction in Cavl .l current (Tang, Ingalls et al. 2004).
  • To determine if calstabinl binding to RyRl has an effect on exercise performance we assessed treadmill run to exhaustion times in mice with muscle-specific deficiency of calstabinl (call-/-). There was a significant defect in the high intensity exercise capacity of call-/- mice compared to WT littermate controls (Fig. 10A). The exercise defect was similar in both males and females (Fig.
  • PDE4D -/- mice exhibit an exercise defect: Global deficiency of PDE4D results in an age-dependent progressive cardiomyopathy (Lehnart, Wehrens et al. 2005). Prior to the age of three months, however, PDE4D-/-mice exhibit no cardiac defect as determined by echocardiogram or cardiac catheterization. The exercise capacity of 2 month-old PDE4D-/- mice was compared with their WT littermates. A significant reduction in exercise capacity was observed (Fig. 1 IA) without any correlation with body weight (Fig. 11B,C,D).
  • CPK levels were increased, consistent with muscle damage at rest, in PDE4D-/ mice relative to WT littermate controls, and there was a significant increase in CPK levels 24 hours following a single episode of eccentric exercise consisting of thirty minutes of downhill treadmill running (Fig. 1 IE) in PDE4D-/- mice.
  • PDE4D-/- mice exhibited an absence of RyRl bound PDE4D3, a small increase in basal RyRl PKA phosphorylation, and a significant increase in calstabinl depletion following only a single day of mild exercise (Fig. 1 IF).
  • FIG. 12A shows that calstabinl rebinding with S 107 had no acute effect on WT exercise performance, but that over time the S 107 treated WT mice were relatively protected against a decline in treadmill exercise capacity that occurred in vehicle treated mice (p ⁇ 0.05 Wilcoxon rank test, S 107 vs vehicle at Day 21). These studies are complicated by the training effect of repeated exercise which leads to improved performance due to enhanced musculature. Individual treadmill failure times on Day 21 are shown in Fig. 12B. Isometric force production was measured in EDL muscles in a tissue bath during field stimulation.
  • EDL muscles from S 107 treated mice showed increased force production at stimulation frequencies greater than 80 Hz consistent with a left-shift of the force-frequency relationship (Fig. 12C). Drug treatment did not result in a change in body weight (Fig. 12D) or muscle weight.
  • Fig. 12E body weight
  • the chronic exercise protocol resulted in substantial PKA phosphorylation of RyRl and calstabinl depletion from immunoprecipitated RyRl .
  • Calstabinl depletion from RyRl was nearly entirely reversed by S 107 treatment (Fig. 12F).
  • Flexor digitorum brevis (FDB) muscle fibers were enzymatically dissociated from mice following the chronic exercise protocol and loaded with the calcium indicator fluo-4. Individual muscle fibers were imaged on a Zeiss Live5 confocal microscope during field stimulation at 1 Hz and during a fatiguing protocol consisting of repeated 300 ms long 120 Hz tetani every 2 seconds for 400 seconds. Representative F/F0 traces during the fatigue protocol are shown for a FDB fiber isolated from a vehicle treated mouse (Fig. 13A) and a Sl 07 treated mouse (Fig. 13B).
  • FDB fibers from S 107 treated mice exhibited a delayed decline in peak tetanic calcium transients (Fig. 13C). It is known that muscle fibers with slower kinetics of Ca 2+ release and reuptake are less prone to fatigue. The kinetics of Ca + release and reuptake during single twitches at 1 Hz were assessed. The distribution of 50% reuptake times (tau) showed no significant differences between vehicle and S 107 treatment (Fig. 17), indicating no shift in the calcium reuptake kinetics of the FDB fibers. These data indicate that treatment with S 107 improves Ca 2+ handling in muscle fibers during fatigue protocols.
  • RyRl calcium release channels become PKA hyperphosphorylated and depleted of the stabilizing protein calstabinl during exercise.
  • the compounds of the invention increase the binding affinity of calstabinl to PKA hyperphosphorylated RyRl .
  • These compounds (referred to as called "calcium channel stabilizers" or “rycal”) are 1,4- benzothiazepines and derivatives thereof. Treatment with these compounds improves exercise performance of mice running on a treadmill.
  • a calcium leak via PKA hyperphoshorylated RyRl channels causes muscle damage due to activation of calcium- dependent proteases and rycals prevent the calcium leak and inhibit muscle damage during chronic exercise.
  • Rycals can be used to improve muscle fatigue in chronic diseases including heart failure, AIDS, cancer, renal failure, and can also be used to treat muscular dystrophies.
  • Duchenne muscular dystrophy is an X-linked muscle disease characterized by mutations in the dystrophin gene. Increased calcium-activated calpain proteolysis in the sarcolemma membrane is thought to be a primary mechanism in the pathophysiology of DMD.
  • the mdx mouse, carrying a stop codon inside exon 23 of the dystrophin gene, provides a useful system to study the effectiveness of different therapeutic strategies for the cure of this disease.
  • a RyCaI compound, S 107 reduces calpain activity in mdx mice during exercise, Figures 7, 18, 19, 20. This indicates that RyCaIs may be useful for treating muscle related diseases, including, but not limited to, muscular dystrophies.
  • mice 21 days old were treated with S 107 (0.125 mg/kg/h) or vehicle using implantable, osmotic pumps for 28 days. After treatment, the mice were subjected to downhill (14degree) treadmill running for 30 min at 18 m/min. Immediately after the exercise, the animals were sacrificed and the skeletal muscles were harvested.
  • EDL Homo senates EDL muscles homogenates were prepared in 0.5 ml of homogenization buffer (20 mM NaF, 10 mM Tris-maleate, pH7.2 + protease inhibitors). Cardiac sarcoplasmic reticulum (CSR) fractions were obtained by centrifuging the homogenates at 50,000 x g for 30 min. Homogenates were centrifuged at 4000 x g for 20 min and the supernatants were centrifuged for 20 min at 10000 x g. Aliquots of the homogenates were assayed for protein concentration and stored at -8O 0 C.
  • CSR Cardiac sarcoplasmic reticulum
  • Calpain Activity Assay Calpain activity of EDL homogenates (30 ⁇ g) were measured using a Calpain Activity Assay kit (Calbiochem). The assay utilizes a synthetic calpain substrate, suc-LLVY-AMC. AMC is released upon cleavage with calpain and is measured fluorometrically. Assays are performed with both an activation and an inhibition buffer to determine specific calpain activity in the sample.
  • Serum Creatine Kinase Serum (10 ⁇ l) proteins were separated using 4-20% '
  • Rhodine Receptor The ryanodine receptor (RyRl) was immunoprecipitated from samples by incubating 250 ⁇ g of EDL homogenate with anti- RyR antibody (2 ⁇ l 5029 Ab) in 0.5 ml of as modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na 3 VO 4 , 0.5% Triton-XIOO, and protease inhibitors) 1 hr at 4 0 C.
  • modified RIPA buffer 50 mM Tris-HCl (pH 7.4), 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na 3 VO 4 , 0.5% Triton-XIOO, and protease inhibitors
  • Lehnart SE Wehrens XH, Laitinen PJ, et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation. Jun 29 2004;109(25):3208-3214. Berchtold MW, Brinkmeier H, Sloner M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiol Rev. JuI 2000;80(3):1215-1265. Gomez AM, Guatimosim S, Dilly KW, et al. Heart failure after myocardial infarction: altered excitation-contraction coupling. Circulation. Aug 7 2001;104(6):688-693.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes de traitement de la fatigue musculaire avec des composés décrits. Elle se rapporte à des compositions et à des méthodes de traitement, de prévention ou de réduction de la fatigue musculaire comprenant l'administration de composés stabilisant les récepteurs de la ryanodine (Tyr), qui régulent le fonctionnement du canal calcique dans les cellules. Des méthodes sont décrites pour traiter la fatigue musculaire chez un sujet souffrant d'un large éventail de pathologies aiguës et chroniques, de maladies ou de troubles neurologiques ou génétiques, comprenant notamment, mais non exclusivement, les maladies cardiaques, l'infection HIV et le SIDA, la dystrophie musculaire, le cancer, la malnutrition, la fatigue musculaire due à l'exercice, la fatigue musculaire due à l'âge, les maladies rénales, et l'insuffisance rénale. L'invention concerne en outre des méthodes pour traiter un sujet souffrant d'une fatigue musculaire résultant d'exercices soutenus, prolongés et/ou astreignants, ou d'un stress chronique.
PCT/US2007/012936 2006-06-02 2007-06-01 Méthodes pour traiter ou réduire la fatigue musculaire WO2008060332A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US81074806P 2006-06-02 2006-06-02
US60/810,748 2006-06-02
USPCT/US2006/32405 2006-08-17
PCT/US2006/032405 WO2007024717A2 (fr) 2005-08-25 2006-08-17 Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
US90434807P 2007-02-28 2007-02-28
US60/904,348 2007-02-28

Publications (4)

Publication Number Publication Date
WO2008060332A2 WO2008060332A2 (fr) 2008-05-22
WO2008060332A9 true WO2008060332A9 (fr) 2008-07-10
WO2008060332A8 WO2008060332A8 (fr) 2008-09-18
WO2008060332A3 WO2008060332A3 (fr) 2008-12-31

Family

ID=39402158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012936 WO2008060332A2 (fr) 2006-06-02 2007-06-01 Méthodes pour traiter ou réduire la fatigue musculaire

Country Status (1)

Country Link
WO (1) WO2008060332A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2012019071A1 (fr) * 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Méthodes de traitement prophylactique et thérapeutique de la sarcopénie
EP2708535A1 (fr) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
US20140128349A1 (en) * 2012-11-02 2014-05-08 Indiana University School of Medicine Administering inhibitors of tgfbeta signaling in combination with benzothiazepine derivatives to improve muscle function in cancer patients
WO2015187649A1 (fr) * 2014-06-03 2015-12-10 Sulfagenix, Inc. Méthodes et compositions destinées à traiter des troubles liés à une carence en oxyde nitrique et des affections associées
JP6962564B2 (ja) 2015-10-08 2021-11-05 株式会社Pal 筋肉損傷や筋肉疲労の抑制剤
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
US11426415B2 (en) 2017-03-06 2022-08-30 Washington University Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
WO2020210521A2 (fr) * 2019-04-12 2020-10-15 The Regents Of The University Of California Compositions et procédés d'augmentation de la masse musculaire et du métabolisme oxydatif
WO2022150603A1 (fr) 2021-01-08 2022-07-14 Armgo Pharma, Inc. Formes cristallines d'un modulateur du récepteur de la ryanodine et leurs utilisations
WO2022246114A2 (fr) 2021-05-20 2022-11-24 Armgo Pharma, Inc. Compositions pharmaceutiques comprenant un modulateur du récepteur de la ryanodine et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064810A (en) * 1990-09-14 1991-11-12 Jeffrey Askanazi Use of branched chain amino acids to effect diaphragm contractility and fatigue
GB9724813D0 (en) * 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue

Also Published As

Publication number Publication date
WO2008060332A2 (fr) 2008-05-22
WO2008060332A8 (fr) 2008-09-18
WO2008060332A3 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2008060332A9 (fr) Méthodes pour traiter ou réduire la fatigue musculaire
AU2006283534C1 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
US20140187536A1 (en) Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP5274831B2 (ja) リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用
EP2653466A1 (fr) Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
US8022058B2 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2012037105A1 (fr) Procédés de traitement, d'amélioration ou de prévention de troubles et de maladies neuronaux induits par le stress
US20070173482A1 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2012019071A1 (fr) Méthodes de traitement prophylactique et thérapeutique de la sarcopénie
KR20070116900A (ko) 라이아노딘 수용체 (ｒｙｒ２)에서의 누출을 표적화하는신규한 항부정맥 및 심부전 약물
TW200815381A (en) Methods for treating or reducing muscle fatigue
MXPA06010857A (en) Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867137

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07867137

Country of ref document: EP

Kind code of ref document: A2